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Abstract: In the last decade, emerging evidence has reported correlations between the gut microbiome
and human health and disease, including those affecting the brain. We performed a systematic
assessment of the available literature focusing on gut bacterial metabolites and their associations
with diseases of the central nervous system (CNS). The bacterial metabolites short-chain fatty acids
(SCFAs) as well as non-SCFAs like amino acid metabolites (AAMs) and bacterial amyloids are
described in particular. We found significantly altered SCFA levels in patients with autism spectrum
disorder (ASD), affective disorders, multiple sclerosis (MS) and Parkinson’s disease (PD). Non-
SCFAs yielded less significantly distinct changes in faecal levels of patients and healthy controls,
with the majority of findings were derived from urinary and blood samples. Preclinical studies
have implicated different bacterial metabolites with potentially beneficial as well as detrimental
mechanisms in brain diseases. Examples include immunomodulation and changes in catecholamine
production by histone deacetylase inhibition, anti-inflammatory effects through activity on the aryl
hydrocarbon receptor and involvement in protein misfolding. Overall, our findings highlight the
existence of altered bacterial metabolites in patients across various brain diseases, as well as potential
neuroactive effects by which gut-derived SCFAs, p-cresol, indole derivatives and bacterial amyloids
could impact disease development and progression. The findings summarized in this review could
lead to further insights into the gut–brain–axis and thus into potential diagnostic, therapeutic or
preventive strategies in brain diseases.
Keywords: gut–brain–axis; gut microbiome; short-chain fatty acids; bacterial metabolites; SCFA
1. Introduction
We are exposed to bacterial organisms from the beginning of our existence to the end
of it. Even before birth, bacteria have been detected in the meconium of newborns, thus
discrediting the pre-existing idea of a sterile foetal stage [1]. Later on, the early postnatal
exposure to either the mother’s vaginal flora or microbes from the environment, depending
on delivery, impacts microbial colonization patterns, overall health and the neurodevel-
opment of the individual [2]. Although the microbial residents in our gastrointestinal
tract (GIT) have already been known to impact the state of human health, the theory of
a bidirectional gut–brain–axis (GBA) has taken the spotlight of global researchers mostly
after the turn of the millennium.
Individuals are globally affected by increasing morbidity and mortality of psychiatric,
neurodegenerative and neurodevelopmental disorders. The aetiology and pathophysiology
of these brain diseases remain to this day to be fully elucidated and treatment options are
largely of symptomatic nature. Therefore, researchers have unsurprisingly been looking
at novel perspectives of disease, such as the GBA. Emerging findings on gut microbial
influence on our nervous system were reported, involving bacterial-derived toxins, vita-
mins and neurotransmitters, yet the precise mechanisms, the “language of the GBA” [3],
remain to be fully elucidated. Some newly examined neuroactive bacterial metabolites
have nevertheless shown potential to play a role in this communication (Figure 1).
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about the GBA’s role in brai
terms “bacterial metabolites” combined with “brain develop-
ment”, “brain aging”, “brain ageing”, “brain disorders”, “brain diseases”, “neurodegen-
erative”, “neuroprotective”, “gut brain axis” and “gut axis” delivered 216 hits after 
Figure 1. Non-exhaustive overview of neuroactive gut bacterial metabolites. SCFAs = short-chain
fatty acids; BA = butyric acid; PA = propionic acid; AA = acetic acid; VA = valeric acid; iBA = isobutyric
acid; iVA = isovaleric acid; iCA = isocaproic acid; TMAO = trimethylamine N-oxide; 3-HBA = 3-
hydroxybenzoic acid; 3,4-diHBA = 3,4-dihydroxybenzoic acid; DHCA = dihydrocaffeic acid; IS = in-
doxyl sulphate; 4EPS = 4-ethylphenylsulfate.
This systematic review intends to summarize the research on various families of
neuroactive bacterial metabolites as probable key players in the GBA. The focus is their
effects on disorders of the brain, ranging from neurodevelopmental stages in childhood to
neurodegenerative diseases in advanced age. Although intriguing evidence has emerged
abou the GBA’s role n tumorigenesis via the modulation of the immune system, we
refer the reader to a recent extensive study [4], as a detailed examination of this subject is
beyond the scope of this review. Considering the magnitude of various influences from
bacterial metabolites on the human organism, we will focus mostly on direct neuroactive
effects on the brain. Most papers have largely emphasized taxonomic shifts in gut micro-
biota in specific diseases, or short-chain fatty acids (SCFAs) to date. One of our objectives is
to provide a summary of findings between SCFAs and brain diseases, while in the second
part of this review, reports of less explored non-SCFAs will take centre stage.
2. Materials and Methods
This systematic review was conducted according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines [5]. The main objective was
to explore and summarize the available data on influences of gut bacterial metabolites on
the brain, with a focus on neurodevelopmental, autoimmune-mediated neuroinflammatory,
and neurodegenerative diseases.
The first PubMed and SCOPUS databank searches were conducted on 20 November
2019. A second search was performed on the 8 July 2020 with the objective to include
additional recently published data. The following search parameters and MeSH (Medical
Subject Headings) terms “bacterial metabolites” combined with “brain development”,
“brain aging”, “brain ageing”, “brain disorders”, “brain diseases”, “neurodegenerative”,
“neuroprotective”, “gut brain axis” and “gut-brain-axis” delivered 216 hits after removing
duplicates (Figure 2). The second search with the same search parameters delivered 76 new
hits. One hundred and forty-seven additional records with relevant information were
individually selected from the list of references of the initially identified papers. Our focus
on gut bacterial metabolites warranted the exclusion of data on viruses, archaea, and fungi
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as well as data on bacteria not related to the gut microbiome. Original papers as well as
reviews were included, while no restriction on publication year was applied. The inclusion
criteria were the following:
• Published in a peer-reviewed article;
• Paper available in full-text PDF;
• Paper available in English;






Figure 2. Methodical approach of our systematic review adhering to Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) criteria (PRISMA criteria [5]).
Most of the papers were dated from 2013 to 2019. Three papers lacking full texts,
as well as two non-English publications, were excluded (Figure 2). Two hundred and
seven papers were further excluded based on the lack of relevance to the topic. Finally,
227 studies were inspected for the qualitative synthesis. As to our knowledge, no other
review to date has undertaken an analysis to this extent of links between several categories
of gut bacterial metabolites and brain diseases.
3. Short-Chain Fatty Acids
Short-chain fatty acids (SCFAs) are saturated fatty acids produced by the bacterial
fermentation of dietary fibre [6]. The majority of SCFAs consist of acetic (AA), propionic
(PA) and butyric acid (BA), which are mostly deprotonated in the intestine (acetate, propi-
onate, butyrate) [7]. Some gut bacterial species capable of generating SCFAs are Bacteroides,
Bifidobacterium, Propionibacterium, Eubacterium, Lactobacillus, Clostridium, Roseburia and Pre-
votella. Among them, Roseburia, Eubacterium and Lachnospiraceae (Firmicutes phylum,
Clostridia class) are strong BA producers, while AA producers belong to the Bifidobacteria
spp. [8]. Considering their production site, the initial point of contact with the human
organism are colonocytes and other intestinal cells. This naturally leads to discussions of
local impacts from SCFAs on overall gut health, predominantly in the context of diseases
like irritable bowel syndrome (IBS) [9–11] and the inflammatory bowel diseases Morbus
Crohn and Colitis Ulcerosa [12,13]. Local effects facilitated by SCFAs have previously been
discussed in detail and will not be further elaborated in this review [12,14,15].
It is known that SCFAs are able to modulate gut permeability by upregulating tight
junction proteins [16,17], which are also part of the blood–brain barrier (BBB). This conceiv-
ably raises the idea that barrier integrity of gut and brain could be similarly affected by
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SCFAs [18]. Indeed, studies in germ-free (GF) mice demonstrated that SCFAs are capable of
modulating BBB permeability, which consequently impacts the extent to which beneficial or
harmful molecules in circulation can reach brain tissue [19,20]. For example, physiological
amounts of PA have been recently shown to protect the BBB from oxidative stress [21] and
to decrease paracellular permeability [22]. Similarly, BA and BA-producing Clostridium
butyricum can lower BBB permeability through enhancing tight-junction expression in
mice [22]. In addition to directly affecting the BBB, SCFAs might actually reduce systemic
inflammation by decreasing gut permeability, thereby decreasing circulating gut-derived
bacterial components that trigger neuroinflammation by injuring the BBB or by affecting
immune cells and cytokines in the brain [15]. SCFAs also act upon various gut–brain–
pathways including immune, endocrine, vagal and direct humoral pathways (extensively
reviewed by Dalile et al. [15]) and some effects in cellular systems, namely:
1. Histone deacetylase inhibition (HDACI) through BA, PA and AA, resulting in up-
regulated gene transcriptions in the context of epigenetic modulation [23,24]. As
extensively reviewed by Stilling et al. [24] with a focus on BA, studies on this subject
are mainly conducted in animal models and in supraphysiological concentrations,
thus the validity of any conclusions drawn from the current evidence is promising,
yet limited for human application as of now.
2. Agonistic effects on G-protein-coupled receptors (GPCRs), namely free fatty acid
receptors FFAR2 (GPR43), FFAR3 (GPR41) and the niacin receptor 1 (NIACR1, also
known as hydroxycarboxylic acid receptor 2 (HCAR2) or GPR109A) [15,25]. Whether
these effects are relevant in humans is to be determined, since current findings on these
GPCRs are mostly based on rodent or cell models. FFAR3 for example, was found
in the CNS and sympathetic ganglia of rats, and in the peripheral nervous system
of mice [15]. Moreover, results linking these GPCRs with microglia cell morphology
and growth hormone secretion in pituitary cells [25,26] call for further research with
a focus on SCFAs as potential bacterial mediators of brain function.
3. Modifications of cellular metabolism and activity in immune cells [27,28]. Similar to
points 1 and 2, findings on these SCFA-mediated mechanisms are currently derived
from animal and cell-based models. Nevertheless, studies have demonstrated striking
results on BA promoting cell metabolism and differentiation in memory T cells [27,28],
which underlines the importance of this mechanism.
4. Regulatory effects on transcription factors like peroxisome proliferator-activated
receptor γ (PPAR-y) and hypoxia inducible factor-1 (HIF-1) [23,25,29] involved in
inflammatory processes were also registered, though studies beyond rodents and cell
models are currently lacking.
These studies have demonstrated SCFAs to be capable of regulating neuroinflamma-
tory processes involving immune cell recruitment and cytokine secretion [29]. Microglia,
immune cells residing in the CNS, were observed to be dysregulated in various psychiatric
disorders like depression, schizophrenia, autism spectrum disorder (ASD) and obsessive–
compulsive disorder [15] as well as in germ-free animals [28]. Interestingly, Toll-like
receptors (TLRs) known to recognize bacterial compounds and to regulate inflammatory re-
sponses in our gastrointestinal tract (GIT) were found on various cell-types of the CNS, thus
further supporting a link between gut and brain immune processes [30]. SCFAs also seem
to directly impact neuronal function, as reported by studies showing PA and BA affecting
intracellular potassium concentrations [31] and findings on influences on neurotransmit-
ter metabolism [15]. Furthermore, beneficial effects on preserving memory function in
experimental meningitis and protection from ouabain-induced hyperlocomotion were
reported through a modulatory effect on the expression and activity of neurotrophic factors
like brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and glial cell
line-derived neurotrophic factor (GDNF) in rats [32,33]. Interesting to note are the effects
on synaptic plasticity by HDACI, since this process involves protein synthesis and there-
fore, gut-derived SCFAs might be potential epigenetic modulators of learning, memory
formation and storage [34,35]. In light of these findings, altered SCFA production in the
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presence of gut microbiome disturbances, also known as dysbiosis, has been postulated as
a potential risk for brain developmental and neurodegenerative diseases. Currently, CNS
pathologies are often associated with changes in taxonomical gut microbiome and bacterial
metabolites, as will be elaborated on in the following chapters.
3.1. SCFA and Autism Spectrum Disorder
Autism spectrum disorder (ASD), a neurodevelopmental disorder characterized by
behavioural abnormalities including repetitive behaviour, communication deficits and
sensitivity to environmental changes, is often linked to gastrointestinal problems and
alterations in the gut microbial community [36–39]. This was shown in a cohort of human
infants, that distinct gut bacterial composition variations, at times called enterotypes,
might correlate with cognitive performance [40]. Recent studies indeed reported the
gut microbiome compositions of children with ASD to be significantly distinct from their
neurotypical (NT) developing peers, and furthermore detected overall lower alpha diversity
in ASD gut microbiomes [41].
Only a handful of human studies have measured faecal metabolites in ASD, with some
of them reporting elevated [42] and others decreased total SCFA levels [39,43] in children
with ASD (Table 1). Contrarily, Kang et al. [41] reported no significant differences in SCFAs
levels between ASD and NT control group. Adams et al. [43] reported lower faecal levels
across all SCFAs (AA, BA, PA, valeric acid (VA)) in children with ASD. Others observed
lower levels of AA and BA, but no significant alterations in PA-levels [44]. Conversely,
significantly increased faecal levels across all SCFAs (AA, BA, PA, VA, isobutyric and
isovaleric acid) in one study [42], and significantly elevated AA and PA in another study
were detected in ASD faecal samples [39,43]. In support of the findings on decreased BA in
two of the studies mentioned, a metagenomic analysis on faecal samples resulted in a lower
abundance of microbial genes involved in the production of BA [38], which also parallels a
prior reported decrease in BA-producing Faecalium prausnitzii in autistic patients [41].
Supporting the idea of gut microbial influence on ASD development, Sharon et al. [45]
demonstrated that faecal microbiome transplants (FMT) from human ASD donors were
able to invoke ASD-like behavioural traits in mice. Moreover, El-Ansary et al. [46] reported
neuronal DNA damage induced by PA oral administration in a hamster model. These
suggested that PA could play a role in neurotoxicity by damaging mitochondrial DNA by
ATP-depletion, thus leading to mitochondrial dysfunction and oxidative stress in neurons.
This postulated pathway in autism has been underscored by earlier findings in rat pups
exposed to PA, exhibiting various immune, mitochondrial and ASD-like behaviour changes
similar to ASD in humans [46–49]. PA-induced ASD in rodents is a validated model for
ASD research that has presented with abnormal neural cell organization and hippocampal
histology, increased microglia activity, neurotoxic cytokine secretion, and typical ASD-like
behaviour traits [50]. Moreover, perturbed microbiota with increased PA-producers and
decreased BA producers correlated with the severity of disease burden in ASD [26,43],
even if studies of PA faecal levels in children with ASD compared to healthy controls (HCs)
have produced conflicting data [39,41].
Contrarily to PA, BA has shown overall beneficial effects in ASD. BA administration
alleviated ASD-like behaviour and normalized changes in gene transcription related to
inhibitory/excitatory balance in the frontal cortex of the T+tf/J strain of the black and
tan brachyury (BTBR) mouse autism model [51]. Nankova et al. [23] reported that SCFA
as epigenetic regulators might affect genes assumed to be involved in ASD. BA and PA
were able to increase catecholamine production as HDACI by regulating the tyrosine
hydroxylase (TH) gene in an in vitro neuronal cell line (PC12 cells). PA and BA also
modulated lipid homeostasis and inflammatory processes [23]. Moreover, SCFAs’ influence
on various genes of the dopaminergic pathway were detected, specifically on dopamine
beta-hydroxylase (DBH) which, when dysregulated, shows associations with ASD in
humans [23]. Interestingly, the serotonin system has been shown to only be affected by the
administration of PA [52]. Furthermore, the study presented downregulating effects by PA
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or BA in the expression of fragile X mental retardation 1 (FMR1), neurexin and neuroligin,
genes previously reported to relate to ASD [53–56]. BA, among all SCFAs, is the most
important HDACI to modulate brain function through epigenetic processes [57] and thus,
altered BA levels might potentially modify neuronal function.
In addition to the potential role of BA and PA in ASD, it is worth noting that the
structurally related valproic acid (VPA), a branched SCFA, effectively creates a frequently
used ASD mouse model that mimics both behavioural as well as gut microbiome traits
in ASD patients [58]. In addition, prenatal exposure to VPA significantly increases the
risk of ASD and showed epigenetic effects on neurotransmitter homeostasis via HDACI,
similarly to BA and PA [59–62]. Additionally, VPA invokes dysfunctions in glutamate
and GABA-neurotransmission and is thus likely to produce an altered balance between
excitation and inhibition in the cerebral cortex [63].
These studies have shown that alterations of SCFAs can intricately influence neurode-
velopmental processes via epigenetic modulation as HDACI. In support of a connection
to ASD, Stilling et al. [64] detected upregulated cAMP response element-binding protein
(CREB)-dependent gene expression in amygdala of GF mice, a limbic structure involved in
emotion, memory and behaviour. It is thus understandable that a dysfunctional amygdala
has been associated with neuropsychiatric disorders like anxiety disorder, post-traumatic
stress disorder (PTSD) and ASD [65].
In contradiction with the above data, no significant changes in SCFA production
were found in GF mice inoculated with microbiota from poor growth and good growth
preterm infants, even though the administered microbiota was associated with pathologic
developmental changes in neurons and oligodendrocytes of the receiving mice [66]. This
might point to a different and/or additional pathway than SCFA, by which gut microbiota
may affect early neurodevelopment.
Overall, support for SCFAs as putative influencers on ASD are present in a handful of
clinical and mainly preclinical studies, though the research is still in its infancy. Therefore,
further investigation to bring light into this emerging theory is strongly recommended.
3.2. SCFAs and Affective Disorders
Pathophysiological factors in affective disorders are multifaceted and gut microbial
involvement has gradually become a potential contributing factor. Faecal SCFA levels from
humans [67,68] and primates [67,68] with major depressive disorder (MDD) showed an
overall decrease and altered composition compared to HCs (Table 1). AA, PA and isovaleric
acid significantly decreased while only isocaproic acid increased in faecal samples of de-
pressed individuals [67,68]. In contrast, one study reported no significant changes in faecal
SCFAs in depressed patients [69]. Nevertheless, researchers previously showed distinct
differences between faecal microbial compositions of HCs and MDD through taxonomic
association studies [70]. Further links between affective disorders and a disturbed gut
environment might be provided through observations in functional gut disorders like
irritable bowel syndrome (IBS), exemplified by the results of a recent meta-analysis with
significantly increased anxiety and depression in IBS patients [71].
A mentionable study by Kelly et al. [69] presented that depressive behaviour can be
transferred from humans to germ-free rats by FMT, suggesting a strong connection between
gut bacteria and affective disorders like major depressive disorder (MDD). Interestingly,
there were discrepant findings regarding the role of SCFAs: faecal AA and total SCFA
levels were higher in rats receiving FMT from patients than from HCs. However, depressed
and healthy human donors showed no significant differences in their faecal SCFA levels.
This calls for further investigations in clinical studies since interspecies differences might
be a contributing factor in this case. Recently, rats bred for high anxiety-like behaviour
(HAB), an animal model for anxiety and depression, displayed lower microglia numbers in
distinct brain regions (infralimbic and prelimbic prefrontal cortex) and gut microbial shifts
toward decreased counts of the BA-producing Lachnospiraceae family [72]. Treatment with
antibiotic minocycline alleviated male HAB rats of depressive symptoms, further decreased
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circulating inflammatory cytokines and microglial count, as well as enriched their micro-
biota with known BA and 3-OH-butyrate producers Lachnospiraceae and Clostridiales
family XIII. In fact, Clostridia are considered as the main BA-producing class of the human
gut microbiome [73] (Table 2). These findings, together with previous propositions for im-
munomodulatory effects of BA and 3-OH-butyrate on inflammation, T-cell and microglial
activity [13,28,29,74,75] point towards an intricate relationship between microbial derived
SCFAs and affective disorders, that might benefit from their anti-inflammatory effects.
In support of this theory, increased markers of inflammation such as pro-inflammatory
cytokines in circulation and the brain are correlated with MDD [76]. Moreover, studies have
successfully demonstrated SCFA-mediated anxiolytic and antidepressant effects in mice
undergoing induced psychosocial stress [77]. In particular, the administration of sodium
butyrate (NaB, the sodium salt of BA) has been reported to alleviate pathologic affective
behaviours in rat models, including hyperactivity, depressive and manic symptoms [26].
Future work on this subject, especially through metabolomic studies in humans, might
enlighten the intricate gut bacterial metabolite–brain axis interplay in affective disorders,
as the current state of research provides only few clinical studies on this particular subject.
3.3. SCFAs and Autoimmune Diseases of the Brain: Multiple Sclerosis (MS)
Multiple sclerosis (MS) is an autoimmune disease of the CNS that mainly damages
the myelin sheaths of motor neurons. An imbalance between anti-inflammatory Treg cells
and proinflammatory Th1 and Th17 cells are widely understood to take part in the MS
pathophysiology [78].
Individuals with MS have been reported to harbour microbiomes that are significantly
different from HCs [79,80]. Indeed, one recent study reported increased Streptococcus,
decreased Prevotella_9 and overall decreased faecal SCFAs (AA, PA and BA) in a Chi-
nese cohort of MS patients [81]. Streptococcus is known to produce all SCFAs [44,82] and
Prevotella_9 is able to generate AA and PA [81] (Table 2). MS patients displayed higher
abundance of inflammatory Th17 cells, as anti-inflammatory Treg cells were decreased.
Interestingly, faecal SCFA concentrations positively correlated with levels of circulating
Treg cells in this study, thus suggesting that SCFAs exert anti-inflammatory effects due to
elevated Treg/Th17–cell ratios. Similarly, significantly decreased SCFAs—were detected in
blood samples of patients with active secondary progressive MS [29]. These two human
studies might suggest an overall decrease in faecal and consecutively depleted circulat-
ing SCFA levels in MS patients (Table 1), that might shift the immune system towards
proinflammatory processes due to lower Treg/Th17 cell ratios.
Autoimmune processes in the CNS were affected by the gut through SCFAs and long-
chain fatty acids (LCFAs) in the experimental autoimmune encephalomyelitis (EAE) mouse
model of MS. The differentiation of pro-inflammatory Th1 and Th17 cells were increased by
LCFAs, while anti-inflammatory Treg cell differentiation was boosted by SCFAs through the
downregulation of the JNK1 and p38 pathway. Therefore, LCFAs exacerbated, while SCFAs
alleviated disease and subdued axonal damage. Additionally, PA demonstrated the most
stimulating effect on Treg cell differentiation, which improved histopathological outcomes
of the spinal cord in EAE mice [13]. Melbye et al. [83] reviewed two other studies in EAE
mice, who supported the ameliorating role of SCFAs in disease activity by modulating an
increase in anti-inflammatory Treg cells and a decrease in pro-inflammatory Th1 and Th17
cells. BA too, was able to ameliorate demyelination in rats and importantly, exposing an
organotypic slice culture to BA resulted in suppressed lysolecithin-induced demyelination
and enhanced remyelination, represented by higher counts of mature oligodendrocytes [84].
In congruence with these studies, a recent review concluded that PA and BA ameliorated
the clinical symptoms of EAE by inducing immune tolerance epigenetically as HDACIs.
The proposed mechanism involves an upregulation of the transcription factor Foxp3
leading to increased Foxp3+ T regulatory lymphocytes, also known as Treg cells that inhibit
proinflammatory Th1 and Th17 cells [85]. In addition to these findings that support an
overall anti-inflammatory effect through SCFAs, Park et al. [29] recently demonstrated
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that SCFA administration to EAE mice models increased anti-inflammatory IL10+Tcells
and IL-10, as well as pro-inflammatory Th1, Th17 and Tc cells. Moreover, SCFA receptors
GPR41 and GPR43 have demonstrated proinflammatory effects in EAE pathogenesis [29].
These results underline the importance of SCFAs to protect from inflammatory processes in
the CNS. Their uncovered pro-inflammatory effects, however, indicate a complex system
in immunomodulation, which calls for further work in this subject in order to evaluate
potential interventions involving SCFAs in neuroinflammatory diseases.
3.4. SCFAs and Neurodegenerative Diseases of the Brain
Neurodegenerative diseases are becoming increasingly prevalent as the population
gradually grows older. Researchers are trying to elucidate the pathomechanisms of the
various brain diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), de-
mentia with Lewy bodies (DLB), multiple system atrophy (MSA) and Huntington’s disease
(HD) [86]. This chapter will first briefly list some findings on SCFAs and neurodegenerative
processes in general before focusing on AD and PD.
3.4.1. General Findings on Neurodegenerative Processes
A recent in vitro study investigated the direct influences of the SCFAs NaB, sodium
valerate and hexanoic acid on neuroinflammation and found that high concentrations
of NaB were able to decrease the basal levels of the proinflammatory cytokine IL-6 in
human glioblastoma–astrocytoma U373 cells [87]. However, further findings showed no
neuroprotection from induced oxidative stress in differentiated SH-SY5Y cells (human-
derived neuroblastoma cells) by any SCFAs. Interestingly, exposure to BA and valerate was
able to induce neuronal maturation through MAP2-gene expression in undifferentiated
neuroblastoma cells, thus hinting towards a beneficial effect on neurogenesis [87]. BA’s
effects in animal models include the potential to alleviate impaired cognition, enhancing
neuronal plasticity, improve learning and memory performance, as well as neuroprotection,
all beneficial processes regarding neurodegenerative diseases [57].
Overall, direct impacts on brain cells by SCFAs seem to be complex as well as dose-
dependent, which supports a hypothesis that anti-inflammatory processes in the brain,
neuroplasticity and neurogenesis could be positively modulated through the manipulation
of gut bacterial production and/or external supplementation of SCFAs. Recent research
further provided evidence for an ameliorating role of SCFAs in inflammatory hippocam-
pal neurodegeneration in mice through the reduced impairment of the intestinal barrier,
which was induced by a high-fructose diet. It was suggested that SCFAs could amend the
faulty colonic NLRP6 inflammasome responsible for epithelial impairment to alleviate hip-
pocampal neuroinflammation, thus possibly reducing the likelihood of neurodegenerative
processes associated with a typically high-fructose Western-style diet [88]. This might be
an indirect mechanism by which SCFAs could exert neuroprotective effects.
3.4.2. SCFAs and Alzheimer’s Disease
Gut microbiome of Alzheimer’s disease (AD) patients were observed to be altered,
with decreased overall richness and diversity as well as some shifts within taxonomical
compositions [89,90]. Some studies presented AD progression to associate with dysbiosis
and that a healthy gut microbiome provides beneficial effects in AD patients and rodent
models [90,91]. Recent studies further showed significant changes in gut microbiome
compositions between AD patients and HCs at the genetic level, suggesting some bacterial
AD-associated PCR products to be a potential marker of AD risk [92]. As Franceschi et al.
described in their review in 2019, disturbances in the gut microbiome might influence
processes involved in AD pathogenesis, such as chronic inflammation, molecular mimicry
and Aβ accumulation. Furthermore, the presence of microbiome enterotype III (low
Bacteroides and Prevotella) and the absence of enterotype I (>30% Bacteroides) were reported
with stronger associations to the presence of dementia than classic markers (Table 3) [93].
This highlights the potential of the GBA to impact pathogenesis in dementia, though
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unfortunately, no human studies that measured SCFA faecal levels have been reported as
to our literature search.
The GF condition in transgenic AD mice models were observed to slow the progres-
sion of disease symptoms [94], underlining an important role for the presence of the gut
microbiome, including bacteria and their metabolites in AD pathogenesis. A study with the
APP/PS1 mouse model of AD reported disturbed microbiota composition and diversity,
as well as overall lower SCFAs levels compared to wild-type (WT) controls. Additionally,
over 30 metabolic pathways possibly related to amyloid deposition and ultrastructural
anomalies were detected in intestine samples of the AD group [95]. Zheng et al. [96] have
introduced a method of stable isotope labelling and liquid chromatography–tandem mass
spectrometry to sensitively detect 21 SCFAs in mice faecal samples of AD and WT mice. In
an AD mouse model, decreased levels of PA, isobutyric acid, 3-hydroxybutyric acid, and 3-
hydroxyisovaleric acid were detected while increased levels of lactic acid, 2-hydroxybutyric
acid, 2-hydroxyisobutyric acid, levulinic acid and valproic acid were found. In contrast
to these findings, faecal PA was enriched in mice receiving FMT from an AD donor in
comparison to a healthy one [97]. However, two faecal donor samples selected out of
groups of 14 healthy and 13 AD volunteers might limit that study’s evidential impact due
to putative inter-individual variations.
The prevention of Aβ accumulation and the removal of accumulated amyloid plaque
have been at the core of anti-AD therapeutic undertakings for more than two decades [98].
It is important to highlight an in vitro study reporting that valeric acid (VA), BA and PA, but
not isobutyric acid, isovaleric acid and AA, to be capable of stopping the misfolding of Aβ40
peptides to neurotoxic Aβ40 aggregates in a dose-dependent manner [99]. Additionally, the
same experiment on Aβ42 aggregation showed that only VA could inhibit the process dose-
dependently. A third experiment determined that VA and BA successfully halted Aβ fibril
formation in a dose-dependent manner. These results demonstrate a mechanism by which
gut microbial-derived SCFAs may benefit AD patients and that a gut microbiome depleted
of SCFA producers might promote neurotoxic amyloid build up in the CNS. In support of
this theory, Sun et al. [100] reported that FMT from WT-mice to the APP/PS1 mice model
of AD resulted in the alleviated brain deposition of Aβ as well as levels of neurotoxic Aβ40
and Aβ42, tau protein phosphorylation, synaptic dysfunction, neuroinflammation and
cognitive deficits, accompanied with restored alterations in gut microbiota and faecal SCFA
levels. The AD mice harboured a perturbed microbiome enriched with Proteobacteria,
Verrucomicrobio (phylum level), and Akkermansia, Desulfovibrio (genus level), with depleted
Bacteroidetes phyla. All these conditions were reversed through FMT treatment. However,
these microbial changes were lacking consistency in the relative abundance of bacterial
species, for example a relative increase in Bacteroidetes or BA-producing Firmicutes has
been previously observed in animal and human studies of AD [91]. Therefore, definite
conclusions about distinct AD gut microbiome compositions and their capacity of SCFA
production cannot be made at this point in time, which further warrants our focus on
disease correlations with bacterial metabolites instead.
Impaired epigenetic gene expression has been discussed as a key factor in AD patho-
genesis [101], which conceivably led to a study of BA’s role as HDACI in an AD mouse
model. Treatment with BA was able to improve associative memory function at an ad-
vanced stage of disease [102]. Other studies mentioned the neuroprotective capacity of BA
to manipulate regulatory regions of the Forkhead box gene locus as HDACI. This provides
a preventative and/or therapeutic potential to affect the balance between life-promoting
and apoptotic cell processes critical in neurodegenerative diseases [8]. BA as NaB has
shown neuroprotective benefits as HDACI in studies of PD, AD and HD, particularly
leading to improved learning and memory in dementia, the prevention of oxidative stress
and neuronal cell death in HD and PD, as well as overall upregulated transcription of
neurotrophic factors involved in plasticity, survival and regeneration [103]. These results
might indicate that decreased or overall altered gut microbial SCFAs and thus, dysregu-
lated histone-acetylation, might indeed be connected to AD and related brain diseases. We
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therefore suggest future studies to look for putative impacts of altered SCFA-producing
gut microbiota on AD-related epigenetic processes in the brain. SCFAs might also impact
AD indirectly through additional pathways via the regulation of intestinal gluconeogenesis
by FFAR3 signalling, which affects the activity of the dorsal motor nucleus of the vagus, a
structure with altered activity in PD and AD [8]. BA especially has also been hypothesized
to positively impact cognition in AD patients via the stimulation of vagal afferents [8].
In a study with rats fed a high-fat diet, it was shown that the administration of
two valeric acid esters (monovalerin and trivalerin) led to higher levels of AA in the
brain, serum and liver, while caecal levels decreased. These data suggest that AA can
actually be increased in the brain by oral supplementation and uptake in the gut [104].
This might be of interest, since AA administration to lipopolysaccharide (LPS)-stimulated
astrocyte cultures was successful in producing anti-inflammatory effects [105]. BA ex-
posure invoked anti-inflammatory effects as well, as shown by the reduced microglial
activation and decreased secretion of inflammatory cytokines. BA inhibits the secretion
of HDAC gut microbe-derived circulating inflammatory cytokines and thus limits their
effects on neuroinflammatory processes that have been postulated to be involved in AD
pathology [91]. Pro-inflammatory cytokines derived from dysbiosis might invoke the
formation of Aβ aggregates as well as cause the dysfunctional maturation of microglia,
thus leading to increased amyloid accumulation in the CNS [91]. Taken together, healthy
gut flora with undisturbed SCFA production might benefit AD patients with decreased
neuroinflammation and amyloid accumulation.
3.4.3. SCFAs and Parkinson’s Disease
PD is, after AD, the second-most prevalent neurodegenerative disease in the world [106]
and is part of a cluster of neurodegenerative disorders associated with aggregated amyloid
proteins. Misfolded alpha-synuclein proteins (αSyn) are specifically implicated in PD,
DLB and MSA, also jointly known as “Synucleopathies” [107]. In PD, the dopaminergic
neurons residing in the substantia nigra pars compacta are lost, subsequently leading to
impaired motor functions [108]. Gut dysbiosis and GI dysfunction have been repeatedly
mentioned as a hallmark of PD [108–114], thus investigations of mechanistic processes
involving the GBA have emerged in recent years. This conceivably led to questions about
gut microbial participation in pathophysiological processes of PD, such as the spreading of
αSyn aggregates from gut to brain via the vagal nerve [115] as well as probable connections
between gut dysbiosis, neuroinflammation and misfolding of αSyn [116].
Overall decreased SCFA levels with relatively low BA and a microbiome with reduced
Bacteroidetes, Prevotellaceae as well as enriched Enterobacteriaceae were reported in
PD [117] (Table 1). Underlining these findings, a recent review reported trends of reduction
in SCFA producers in a PD patient’s microbiomes, specifically reduced Lachnospiraceae
(Blautia, Dorea, Coprococcus, Rosburia, Clostridium XIV), Faecalibacterium and Bacteroides [109].
Interesting to mention is the overall increased abundance of Enterobacteriacea, a phylum
that is known to produce SCFAs (Table 2) and to also associate with the severity of motor
symptoms in PD patients [112]. This finding might at the first glance appear counterin-
tuitive under the assumption that SCFAs and their producers are beneficial to PD. On
the other hand, the relative abundance in Enterobacteriaceae might further indicate the
production of other metabolites involved in PD, as will be elaborated on later in the chapter
discussing bacterial amyloids.
Two studies in rodents reported further contradicting results regarding SCFA levels
in PD. Sampson et al. [118] used a transgenic αSyn-overexpressing mouse model of PD,
that presented ameliorated PD pathologies when in a germ-free (GF) state or treated
with antibiotics (AT). These GF/AT mice were then inoculated with human PD-donor
microbiota. This treatment significantly altered faecal microbial communities and SCFA
composition, displaying lower AA, but higher PA and BA, as well as worsened motor
dysfunction compared to those receiving healthy FMT. Thus, the administration of a
mixture of SCFAs to GF/AT mice was effective in inducing motor deficits, as well as
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αSyn aggregation and microglial activation in the brain. This suggested a relevant role
for SCFAs as mediators of PD in a genetically susceptible animal model [118]. Supporting
these findings, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP) – induced PD
mice model presented an increased abundance of faecal SCFAs. The gut microbiome of
this PD model was administrated to normal mice, which resulted in motor impairment
and decreased striatal neurotransmitters, while FMT from healthy donors alleviated those
symptoms [119]. The inconsistencies within the previously mentioned studies in human
subjects, regarding beneficial or detrimental effects of SCFAs in PD, might point towards
inter-species differences of mice and humans and the GF state of acutely inoculated mice.
This could further suggest that even though the presence of SCFAs seems necessary to
trigger pathological changes in genetically vulnerable organisms, shifts towards depleted
SCFA levels and their bacterial producers might play a role in already established PD.
Several lines of evidence suggest that SCFAs, BA in particular, may exert possible
beneficial effects in PD. First, BA might play a role in PD as a neuroprotective agent
due to its agonistic effect on the receptor GPR109A, which promotes anti-inflammatory
processes [120]. In addition, BA might also benefit PD patients with reduced neuroinflam-
mation, indirectly enhanced dopamine synthesis through increased free niacin levels, as
well as improved energy homeostasis and mitochondrial function [103,121]. Lastly, SCFAs
ameliorated dysfunctional microglia in GF mice, which was represented by improved
microglial maturation, morphology and function [28]. Proper mature microglial function
includes decreased inflammatory activity and phagocytosis for amyloid proteins like tau,
Aβ, and αSyn. Therefore, the state of the gut microbiome and its production power for
SCFAs might positively influence several aspects of neurodegenerative diseases [91]. It
might be of interest that mice lacking the SCFA receptor FFAR2 have shown dysfunctional
microglia similar to GF animals, however, that particular study suggested alternative path-
ways by which SCFAs directly exert their effects on microglia due to a lack of evidence for
FFAR2-expression on CNS cells [28]. Definite mechanisms involved in receptor-mediated
processes of SCFAs remain to be determined.
As previously mentioned, SCFAs can upregulate gene-expression as HDACI. This
process was shown to facilitate neuroplasticity and long-term memory, involving CREB-
dependent gene regulation [122,123]. In vitro studies also discovered PA and BA to mod-
ulate transcription of the tyrosine hydroxylase gene in brain cells and thus to influence
catecholaminergic biosynthesis [23]. Catecholamines like DOPA, dopamine (DA), nora-
drenaline and adrenaline are essential neurotransmitters with important roles in brain
diseases, exemplified by the depletion of DA being a key factor in PD [52,106,124]. Espe-
cially relevant to PD is that the enzyme tyrosine hydroxylase catalyses the rate-limiting step
of DA synthesis [8]. Further research on BA’s role as HDACI revealed protective effects
for dopaminergic cells, namely rescuing them from αSyn-mediated DNA damage [125] or
MPP+-induced toxicity [126] through an enhanced expression of DNA damage response
genes. Supporting evidence come from a study in a drosophila model of PD in which
BA has been reported to alleviate motor dysfunction and mortality [127]. Moreover, al-
tered gut levels of SCFAs and neurotransmitters were associated with the surface area of
the insula [9], a brain region that is understood to be dysfunctional in neurological and
psychiatric disorders [128].
The influence of gut microbiota on PD might further impact the conventional therapy
of levodopa administration, since the abundance of the gene for tyrosine decarboxylase, an
enzyme converting levodopa to DA, in the microbiome of PD patients correlates with higher
dosage needs for levodopa/carbidopa. Furthermore, it was shown in rats, serum levels of
the aforementioned drug negatively correlated with the host’s microbiome tyrosine decar-
boxylase gene levels [129]. These findings might provide the base for further clinical studies
on gut microbial modulations in PD patients with increased levodopa/carbidopa dosages.
Taken together, SCFAs seem to exert overall beneficial effects on the CNS regarding
autoimmune brain diseases and neurodegenerative diseases. However, preclinical findings
on probable detrimental effects upon SCFA exposure in rodents suggests that these bacterial
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metabolites might function as double-edged swords when it comes to brain health. Thus,
the thorough examination of these mechanisms is crucial before future potential therapeutic
and preventative strategies can be unequivocally suggested.
Table 1. SCFA level alterations in brain diseases found in human studies.
Disease SCFA Literature p-Values
ASD
AA
↓ f [44], f [43] p = 0.011, p = 0.0000003
↑ f [42], f [39],* u [36] p = 0.037, p < 0.005, p < 0.005
- f [41] p = 0.979
BA
↓ f [44], f [43] p = 0.005, p = 0.005
↑ f [42] p = 0.025
- f [41] p = 0.974
Isobutyric acid ↑ f [42] p = 0.022
Isovaleric acid ↑ f [42] p = 0.038
PA
↓ f [43] p = 0.002
↑ f [42], f [39] p = 0.007, p < 0.005
- f [41], f [44] p = 0.979, p = 0.243
VA
↓ f [43] p = 0.005
↑ f [44], f [42] p < 0.001, p = 0.007
MDD
AA
↓ f [67] p = 0.04
↑ f [69] p = 0.65
BA - f [67], f [69] p = 0.68, p = 0.867
Caproic acid ↑ f [67] p = 0.09
Isobutyric acid
- f [67] p = 0.70
- f [69] p = 0.501
Isocaproic acid ↑ f [67] p < 0.01
Isovaleric acid - f [67] p = 0.4
PA
↓ f [67] p = 0.07
- f [69] p = 0.918
VA ↓ f [67] p = 0.56
MS
AA ↓ f [81], s [29] p < 0.0001, p = 0.001
BA ↓ f [81], s [29] p < 0.05, p = 0.0001
Isovalerate, valerate,
hexanoate, heptanoate
- s [29] p > 0.05
PA ↓ f [81], s [29] p < 0.0001, p = 0.01
PD
AA ↓ f [117], * p [109] p < 0.01, p = 0.0201
BA ↓ f [117] p < 0.01
Isobutyric acid - f [117] p > 0.05
Isovaleric acid - f [117] p > 0.05
PA ↓ f [117] p < 0.01
VA - f [117] p > 0.05
This table shows the differences of SCFA levels of various sample materials from human patients compared to healthy controls. Significance
of the data is given in the last column. ↑ symbolizes increased, ↓ decreased, whereas - symbolizes no significant change in metabolite levels
found in cohorts with the specific disease. Sample material is noted as f = faecal; s = serum; p = plasma; u = urine with the associated
reference as numbers in brackets; p-values < 0.05 are marked in bold letters. BA = butyric acid; AA = acetic acid; PP = propionic acid; VA =
valeric acid; ASD = autism spectrum disorder; MDD = major depressive disorder; MS = multiple sclerosis; PD = Parkinson’s disease. “*”
marked references are sourced from reviews.
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Table 2. Gut-residing bacteria found to correlate with the production of SCFAs.
SCFA Taxa Study
tSCFA Faecalibacterium, Ruminococcus, Bifidobacterium [39]
PA Bacteroides [39]
VA Acidobacteria, Actinomycetaceae [44]
BA
Streptococcaceae, Peptostreptococcaceae, Lactobacillaceae, Clostridiaceae,
Family_XIII, Leuconostocaceae
[44]
PA Desulfovibrionaceae, Streptococcaceae [44]
AA Desulfovibrionaceae [44]
AA, PA Prevotella_9 [81]
BA Clostridium, Eubacterium, Butyrivibrio [103]
AA Bacteroidetes, B.hydrogenotrophica [130]
BA Lachnospiraceae, Faecalibacterium prausnitzii, Eubacterium, Roseburia [130]
PA Bacteroidetes, Proteobacteria, some Lachnospiraceae [130]
BA Eubacterium ramulus [131]
PA Clostridium [46]
AA, PA Parabacteroides distasonis, Megaspheara massiliensis [87]
BA, VA, HA Parabacteroides distasonis, Megaspheara massiliensis [87]
PA Lactobacillus, Propionibacterium [97]
BA
Faecalibacterium prausnitzii, Eubacterium rectale, Roserburia, Eubacterium hallii,
Ruminococcus bromii
[14]
PA Akkermansia municiphila [14]
BA Blautia, Lachnospiraceae: Coprococcus, Roseburia, Faecalibacterium, Lachnospira [132]
BA Clostridia (class) [73]
AA Blautia hydrogenotrophica, Clostridium, Streptococcus [82]
PA
Salmonella, Roseburia inulinivorans, Ruminococcus obeum, Bacteroides, Phascolarctobacterium
succinatutens, Dialister, Veillonella, Megasphaera elsdenii, Coprococcus catus
[82]
BA
Anaerostipes, Coprococcus catus, Eubacterium rectale, Eubacterium hallii, Faecalibacterium
prausnitzii, Roseburia, Coprococcus comes, Coprococcus eutactus
[82]
tSCFA = total SCFAs; BA = butyric acid; AA = acetic acid; PP = propionic acid; VA = valeric acid; HA = hexanoic acid. References are
represented by numbers in brackets.
Table 3. Prevalence of dementia linked with various factors.
Factors Odds Ratio p-Value
Enterotype III 18.5 b <0.001 b
Enterotype I 0.1 a <0.001 a
ApoE 3.9 a, 4.4 b 0.035 a, 0.026 b
SLI 15.0 a 0.005 a
VSRAD 3.5 a, 4.2 b <0.001 a,b
Multivariable logistic regression analysis models linking the prevalence of dementia and various factors from
Saji et al. [93]. a Model 1: inclusion of enterotype I, b Model 2: Inclusion of enterotype III. Abbreviations: ApoE
ε4 = apolipoprotein ε4; SLI = silent lacunar infarct; VSRAD = voxel-based specific regional analysis system for
Alzheimer’s disease.
4. Non-SCFA Bacterial Metabolites
The vast majority of current studies on the GBA involve SCFAs. Our gut microbiota,
however, produces metabolites far beyond the products of fibre degradation, including
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vitamins, polyphenol metabolites and products from amino acid metabolism (Figure 1).
Each of these families of compounds are involved in various pathways and contain potential
neuroactive metabolites [22]. This warrants our curiosity in exploring non-SCFA bacterial
metabolites as contributors to the GBA.
4.1. Amino Acid Metabolites
Metagenomic studies suggests human gut microbes to be largely involved in amino
acid metabolism [133]. Of special interest are the aromatic amino acids (AAA) tyrosine
(Tyr), phenylalanine (Phe) and tryptophan (Trp). Humans are unable to produce AAA
and depend on dietary sources and our gut microbiome for covering their nutritional
needs. Gut bacteria are able to synthesize all three AAA de novo via the shikimate
pathway [92,134]. In a first step, Trp and Phe are biosynthesized. Tyr is then synthetized
from Phe. Further AAA metabolism occurs in the host as well as in gut microbes like
Lactobacillus, Enterobacteriaceae and anaerobes of the phylum Firmicutes, that generate
other metabolites. Phe and Tyr are catabolized in animals to neurotransmitters, including
L-Dopa, DA, epinephrine and norepinephrine, while gut bacteria are able to produce
phenolic compounds like p-cresol from Tyr and phenyl molecules from Phe. Trp is an
essential precursor for the neurotransmitters serotonin and tryptamine, as well as vitamin
B3 (niacin), redox cofactors NAD(P)+, plus metabolites from the kynurenine pathway [134].
On note, the kynurenine pathway in gut microbes generate metabolites associated with
brain functions like indole, indole-derivatives, kynuric acid and quinolinate, which will be
elaborated on in the following chapters. For a more in-depth analysis of AAA metabolism
in plants, microbes as well as mammals, we refer the reader to the extensive review by
Parthasarathy et al. [134].
Considering the previously described processes in AAA metabolism, it is conceivable
to assume that gut microbiota might modulate neurotransmitter metabolism, synthesis,
and availability in the gut, the circulatory system and the CNS. In fact, the abundance
of circulating Trp can be curbed as a result of gut microbial Trp metabolization through
other pathways, thereby possibly limiting the precursor for neurotransmitter synthesis in
the CNS while also generating other neuroactive metabolites like indole and its deriva-
tives [135] (Figure 3). On the other hand, gut microbes seem to elevate serotonin plasma
availability after colonizing GF animals, leading to the assumption that the presence of
a functioning gut microbiome contributes to physiological serotonin plasma levels [136].
More importantly, a recent study observed gut microbial involvements in Trp metabolism,
providing an extensive overview of six pathways, each generating neuroactive metabolites
referred to as “TRYP-6”, consisting of kynurenine, quinolinate, indole, indole acetic acid
(IAA), indole propionic acid (IPA) and tryptamine [135]. They identified five common gut-
inhabiting phyla capable of two to six pathways. The five phyla Actinobacteria, Firmicutes,
Proteobacteria, Bacteroidetes and Fusobacteria thus have been suggested to relevantly influ-
ence Trp metabolism. Investigations on a genus level revealed that Clostridium, Burkholderia,
Pseudomonas, Streptomyces and Bacillus were particularly capable of generating neuroactive
Trp metabolites, with the first two holding the highest potential (Table 4). Numerous
pathways and metabolites in the AAA metabolism, especially Trp, show relevant effects
on the CNS that seem to be intricately complex and crucial for proper brain function, thus
pointing to these non-SCFAs as promising players on the GBA (Figure 3).
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Figure 3. Hypothetical influences on brain diseases by gut bacteria-derived tyrosine and tryptophane metabolites. This
figure illustrates the mechanistic effects by which gut microbial metabolites might influence brain functions related to
autism spectrum disorder (ASD) and neurodegenerative disorders (NDs): Parkinson’s disease (PD), Alzheimer’s disease
(AD), multiple sclerosis (MS) and psychiatric disorders (PsyD). Gut bacteria taking part in metabolite production are
listed in black boxes situated under the orange (tyrosine metabolites) and blue boxes (tryptophane metabolites). Arrows
accompanied with + or − represent an agonistic (+) or antagonistic (−) effect on a receptor, whereas unaccompanied
arrows symbolize an effect described in the white boxes. ↑ = upregulated, ↓ = downregulated or lowered levels of.
ROS = reactive oxygen species; NMDA-R = N-methyl-D-aspartate receptor; Trp = tryptophane; AHR = aryl hydrocarbon
receptor; 4EPS = 4-ethylphenylsulfate; IPA = indole-propionic acid; IAA = indole-acetic acid; kyn = kynurenine; quin = quino-
linate; trypt = tryptamine; i.a. = inter alia.
4.1.1. AAMs and Neurodevelopmental Disorders
P-cresol is a known uremic toxin, which is metabolized into p-cresol sulphate by
the liver [137] and is believed to derive from Tyr fermentation in several gut bacterial
species (Table 4). Significantly increased urinary and faecal levels of p-cresol were re-
ported in autistic children, with some linking urinary levels with the clinical severity of
disease [39,41,138,139]. Interestingly, p-cresol levels significantly and negatively correlate
with age in ASD patients, which might suggest that younger individuals with ASD are
exposed to effects from elevated p-cresol levels [41]. One study, however, did not detect
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significantly altered faecal levels in children with ASD [42]. As for non-human studies,
p-cresol was very recently shown to dose-dependently induce and exacerbate ASD-like
behaviours and significantly activate dopamine (DA) turnover in brain regions (amyg-
dala, nucleus accumbens and striatum) in the genetically vulnerable BTBR mice model for
ASD [140]. Social avoidance behaviour and increased gut levels of p-cresol were detected
in GF mice, inoculated with p-cresol-producing Clostridiales (including Lachnospiraceae
and Ruminococcae families), and these mice associated with defective myelination in
the prefrontal cortex [141]. Additional in vitro testing showed that exposure to p-cresol
interrupted the differentiation of progenitor cells into oligodendrocytes [141], suggesting
that gut microbial p-cresol might impact CNS myelination through transcriptional changes.
Other mechanisms by which p-cresol might negatively impact neuronal functions [140]
include the inhibition of dopamine-β-hydroxylase and membrane depolarization with
higher vulnerability for seizures and blunted Na+/K+-ATPase function. These mechanisms
might demonstrate a potential for gut bacterial-derived p-cresol to play a role in disorders
with disfunctions in the CNS, including ASD, MS, and neurodegenerative diseases.
In the maternal immune-activated (MIA) mouse model of autism spectrum disorder,
changes in serum metabolites, showing significant elevations of two AAA bacterial metabo-
lites 4-ethylphenylsulfate (4EPS) and indolepyruvate were found, which were completely
normalized along with ASD-related behaviour, dysbiosis and impaired gut barrier after the
inoculation with the probiotic B. fragilis [142]. Moreover, WT mice treated with the metabo-
lite 4EPS alone manifested anxiety-like behaviour similar to MIA-mice, thus suggesting a
compelling association between 4EPS and ASD. Additionally, other metabolites, two of
them being serotonin and p-cresol, were elevated in the serum of MIA-mice, though not at
significant levels [142]. It is essential to mention 4EPS’s structural similarity to the prior
mentioned p-cresol, which has links to ASD and is believed to share its producers in the
gut with 4EPS, namely Clostridia spp. [36,140,142] (Table 4). Overall, preclinical data and
some supportive human studies point towards a connection between 4EPS, indolepyru-
vate, p-cresol and ASD, not only as biomarkers of disease but also as putative mediators
of pathogenesis.
With an extensive in silico study, Kaur et al. [135] recently detected the aforementioned
“TRYP6”, the six Trp metabolism pathways generating neuroactive metabolites, to be en-
riched in the metagenome of autistic gut microbiota. Genomes of the genera Burkholderia
and Pseudomonas showed particularly large potentials for TRYP6 metabolism. Burkholderia
holds pathways for kynurenine and quinolinate, with a lower production of IAA, indole
and tryptamine, while Pseudomonas is a strong producer for kynurenine and a weaker
one for IAA, quinolinate and tryptamine. Other enriched pathways in autistic children
consisted of those generating indole and its derivative IAA by already mentioned genera
Burkholderia and Pseudomonas plus Corynebacterium. Though microbiota from NT individu-
als also harboured some relatively enriched bacteria capable of producing TRYP6, namely
Alistipes for indole and Eggerthella for IAA production, these genera are comparatively
weak producers and thus, theorized to use indole and IAA as inter-bacterial communi-
cation tools [135]. Similarly, altered Trp metabolism in ASD has been indicated through
significantly increased urinary levels of IAA, indoxyl sulphate (IS, also known as indican)
and indolyl lactate in autistic children [143], though to date no data on faecal levels have
been found.
In addition to Trp metabolism, altered Phe metabolism in autistic children were re-
cently highlighted, partly based on evidence of significantly elevated Clostridia-generated
Phe metabolites in the urinary profiles of ASD patients including 3-(3-hydroxyphenyl)-
3-hydroxypropionic acid, 3-hydroxyphenylacetic acid and 3-hydroxyhippuric acid [36].
However, whether these metabolites might be modulated by gut bacteria remains to
be elucidated.
Increased faecal levels of glutamate in children with ASD, as well as decreased GABA
levels in those with pervasive developmental disorder not otherwise specified (PDD-NOS)
have been previously reported [39]. Kang et al. [41] have similarly detected lower GABA
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faecal levels in autistic children, though these did not reach significance (p = 0.077). Preclin-
ical observations in altered GABA and glutamate levels were made in a study invoking
behaviours associated with ASD in GF mice through inoculation with gut microbiota
derived from autistic patients. In comparison, mice receiving healthy donor FMT did not
produce ASD-like behaviour [45]. Moreover, lower faecal levels of the GABA A receptor
agonists 5AV and taurine were found in the first group, supporting a putative role of
disturbed GABA signalling in ASD. In a further step, the exposure of an ASD mouse
model to taurine or 5AV during the prenatal and weaning period produced mice with
ameliorated ASD behaviour in comparison with mice treated during their juvenile stage
and older mice. This suggests a critical window of vulnerability for disturbed GABA
signalling during neurodevelopment [45]. Other researchers were able to uncover cor-
relations between gut microbe genes associated with neurotransmitter metabolism and
the surface area of the insula, with a focus on two microbial genes involved in GABA
and glutamate metabolism, namely 4-hydroxybutyrate dehydrogenase and glutamate
dehydrogenase [9]. As already mentioned, the insula is thought to be dysfunctional in
many psychiatric disorders with disturbed emotion, cognition and motivation, such as
affective, neurodevelopmental and neurodegenerative disorders [128]. However, it is also
important to note that Kang et al. [41] were not able to detect any significant changes
in gut bacterial pathways by PICRUSt database analysis between ASD and NT children.
Nevertheless, these studies accumulatively show the potential involvement of gut micro-
bial metabolites in disturbed GABA and glutamate signalling in ASD pathophysiology.
Further metabolomic, metagenomic and microbial analyses of faecal amino acid metabo-
lites (AAMs) are nonetheless highly encouraged. Compellingly, a recent study reported
that GABA produced from gut bacteria (E. coli HT115 and P. aeruginosa PAO1) was able to
protect from neurodegeneration in the nematode C. elegans [144].
Lastly, the amplified metabolism of the amino acids Tyr, lysine, cysteine and methion-
ine in healthy children’s gut microbiomes have been found, which implies a supportive
function of gut commensals during brain development, since the mentioned amino acids
are not only substrates for the synthesis of structural proteins, but also neurotransmitters
and biogenic amines [145].
4.1.2. AAMs and Psychiatric Disorders
No specific studies on non-SCFA faecal metabolites have been found in humans with
affective disorders. However, there are a handful of reports pointing to correlations be-
tween disturbed gut microbial Trp metabolism and psychiatric disorders like anxiety and
depression. Studies on acute tryptophan depletion (ATD) in humans demonstrated a corre-
lation between the reduced levels of circulating Trp and depressive symptoms in patients,
who are responsive to treatment with selective serotonin reuptake inhibitors [146,147].
ATD has also been shown to worsen depressive symptoms in patients in remission, as well
as in healthy volunteers at high risk for depression [70]. Furthermore, 5-HT levels in the
CNS were shown to be impacted by the amount of dietary Trp in humans [147]. This raises
the question of whether a disturbed gut microbial Trp metabolism could deplete circulating
Trp availability and consecutively impact 5-HT homeostasis in the CNS. The impact of
gut microbiota, or the lack thereof, on the host’s nervous system can be explored in GF
raised animals providing the evidence for altered levels of neurotransmitters in the brain
in comparison to conventionally raised control animals [148]. In support of the previous
reports on humans, a recent study in GF mice showed initially higher Trp and 5-HT brain
levels together with a less depressive behaviour at baseline and intriguingly, decreased
Trp and 5-HT with enhanced depressive behaviour after ATD compared to the control
group (specific pathogen-free mice) [149]. Additional support was obtained by findings
in a rat model, which showed an induced depression to invoke gut microbial alterations
as well as noticeable faecal metabolite shifts [150]. Sixteen metabolites were evaluated to
be significantly distinct enough to function as depression biomarkers, including altered
Trp metabolites (upregulated dextrorphan O glucuronide, 3-methyldioxyindole and down-
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regulated 5-methoxytryptophan) (Table 5). The others consisted of bile acid metabolites
(upregulated) as well as hypoxanthine (upregulated) and fatty acid metabolites (downreg-
ulated). Additionally, the altered gut microbiota also resulted in changes of catecholamine
levels in the hippocampus of depressed rats, specifically serotonin (5-HT) and DA [150].
Similarly, Clarke et al. [151] found elevated levels of 5-HT and 5-HIAA in hippocam-
pal structures of GF male mice, as well as higher plasma levels of their precursor Trp.
Considering that CNS Trp levels are to a great extent regulated by its abundance in plasma,
this supports the conjecture of a humoral pathway through which gut microbes could
influence serotoninergic neurotransmission by modulating Trp availability [148]. Fascinat-
ingly, it was not possible to reinstate altered hippocampal 5-HT levels through inoculation
with an intestinal microbiota in GF mice at a later stage of life, even though the serum
levels of Trp were normalized. This points to a critical time window in which microbial
Trp metabolism could directly impact neurodevelopment [152]. Additionally, GF animals
displayed elevated stress reactivity, represented with higher corticosterone production,
while also expressing lower anxiety-like behaviour that was normalized after recoloniza-
tion [148]. This is intriguing, since stress hormones like cortisone shift Trp metabolism
away from 5-HT production to the kynurenine pathway that generates kynurenic acid,
quinolinic acid and picolinic acid [153]. While kynurenic acid invokes antagonistic effects
on the α7 nicotinic acetylcholine receptor and the N-methyl-D-aspartate (NMDA) receptor,
quinolinic as well as picolinic acids are agonists of the NMDA receptor with neurotoxic and
depression-producing properties [152]. It is also noteworthy, that a previously mentioned
study on ASD reported the induction of anxiety-like behaviour in mice following the
administration of the microbial Trp metabolite 4EPS [142]. Overall, these studies might
provide tangible evidence for gut microbial impact on depressive and anxious behaviour
by regulating the availability of circulating Trp and consecutively, levels of Trp metabolites
like 5-HT, kynurenic, quinolinic and picolinic acids. However, clear associations between
gut microbial Trp metabolites and depression or anxiety seem too early to be made since
studies on this subject are largely based on preclinical settings on animals.
Indole is partly produced from dietary tryptophan through the enzyme
tryptophanase [154] mainly by gut bacteria Escherichia, Citrobacter, Fusobacterium, Bac-
teroides, Clostridium_XIX, Desulfitobacterium, Edwardsiella, Providencia and Shigella [135]
(Table 4). Indole has also recently been shown to be associated with impaired motor
activity, anxiety and depression in rats when acutely or chronically overproduced [155].
Probable pathways by which these effects occur are the activation of vagal afferences by
indole and on the other hand, accumulation of oxidized indole derivatives like oxindole
and isatin in the brain. Indole has been shown to activate gut mucosal L-cells to secrete
glucagon-like peptide-1 (GLP-1), which then stimulates vagal afferent fibres, therefore pre-
senting an indirect impact of indole on the CNS [156]. Oxindole is known to inhibit motor
activity [155], invoke hypotension, loss of righting reflex and a reversible comatose state,
while isatin is proposed an anxiogenic role by inhibiting monoamine oxidase (MAO) B and
by producing antagonistic effects on benzodiazepine receptors in rodents [70]. However,
Jaglin et al. [155] showed that while acute overexposure to indole in the rat gut produced
depressant effects on motor activity and elevated levels of oxindole and isatin the brain,
chronic exposure to indole-producing E. coli induced depression-associated traits (anxiety-
like and helplessness behaviours) without an accumulation of oxindole and isatin in the
CNS. This suggests that an indole-overproducing gut microbiome might be a risk factor for
the development of anxiety and depression, while acute spikes of indole-production might
profoundly decrease locomotion by the central accumulation of oxindole and isatin as well
as activation of vagal afferences. Studies have further demonstrated vagal GBA connections
to neurons related to reward centres, thus pointing towards a probable pathway for gut
metabolites to influence the brain in neuropsychiatric disorders with disturbed reward sys-
tems [157]. A recent in silico study on microbial Trp metabolism pathways in neurological
disorders called for further investigations of the gut microbiome in schizophrenia, since
assumptions were too early to be made on one single available dataset, that showed altered
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indole, IAA and tryptamine pathways in the microbiome of schizophrenic patients [135].
The research of gut microbial influence on schizophrenia is still in its infancy, which is
represented by very few analyses on microbiome compositions and no study on faecal
metabolomes in schizophrenic cohorts so far. With the emerging correlations between other
brain disorders and the microbiome, as well as some preclinical information on dysbiosis
and probiotic studies in schizophrenia [158], further work on this particular subject remains
wanting of exploration. Taking all these studies into consideration, tryptophan metabolism
with its manifold metabolites seem to be intricately influenced by gut microbial metabolites
and to be implicated in psychiatric disorders and brain functions.
4.1.3. AAMs and Neurodegenerative Diseases
Alzheimer’s Disease
A limited number of studies have indicated adverse effects on neurons in the context
of Alzheimer’s disease (AD) by Trp metabolites. The decarboxylated molecule tryptamine
has been associated with neurotoxicity and neurodegeneration [92,159–161] (Figure 2).
Tryptamine producers commonly found in gut flora are Holdemania, Desulfovibrio, Yersinia,
Tyzzerella, Bacillus, Clostridium and Ruminococcus [135] (Table 4). Most recent findings
showed gut bacterial genomes in faecal samples of AD patients, of which one gene sequence
encodes the enzyme Na-transporting NADH:Ubiquinone reductase (in Clostridium sp.),
which produces the neuroprotectant ubiquinone. Interestingly, that enzyme is also involved
in the metabolic synthesis of AAA [92]. Underlining these findings in AAA metabolism,
Trp and Tyr (also GABA, taurine and valine) were found to be decreased in faecal samples
of mice receiving FMT from an AD patient [97], though as noted in a previous chapter, two
faecal donor samples selected out of groups of 14 healthy and 13 AD volunteers might
limit the evidential impact by probable inter-individual variations.
Regarding the theory of a perturbed Trp metabolism in AD, microbial and hepatic
enzymes generate kynurenine from Trp, and in succession, kynurenic acid or quinolinate.
Quinolinate shows excitotoxic properties as an NMDA receptor agonist, whereas kynurenic
acid ameliorates those neurotoxic effects as NMDA receptor antagonist. Therefore, this
might provide a probable link between Trp metabolites and neurodegenerative processes in
AD (Figure 3). In contrast to those findings, in aberrantly elevated amounts, kynurenic acid
has been linked to cognitive impairments, probably caused by its antagonistic effect on the
α7-nicotinic acetylcholine receptor [152]. It should be emphasized that CNS kynurenine
mostly originate from the periphery and that its metabolization into kynurenic acid and
quinolinate takes place in the CNS [151]. Some gut genera Bacillus, Burkholderia, Streptomyces
and Pseudomonas are specially equipped for kynurenine production, while Klebsiella, Bacillus
and Burkholderia are efficient quinolinate producers [135].
Another Trp metabolite generated from gut microbiota is indoxyl sulphate (IS), an ure-
mic retention toxin in patients with chronic kidney disease, which has been associated with
cognitive impairments [162] and various diseases of the brain such as AD, PD, MDD and
MS [163]. IS was previously observed to induce nuclear factor-kappaB (NF-κB)-mediated
oxidative stress in animal and in vitro studies [163,164]. Moreover, it exhibited potential
neurotoxic effects in mice through perturbed microglial and astrocyte function, resulting in
neuronal death [165]. This might be of interest since oxidative stress is proposed as a major
process in neurodegenerative diseases [166]. Underscoring these correlations, researchers
observed an elevated cerebrospinal fluid (CSF)/plasma ratio of IS in patients with PD
compared to healthy counterparts [163]. This might suggest the increased crossing of IS
through the BBB, a process probably facilitated by increased BBB permeability in diseases
like AD and PD [167]. On the other hand, decreased IS levels in CSF, serum and faecal
samples of GF and AT mice have been associated with perturbed fear extinction learning
processes. These defects are common in anxiety and fear-related diseases with impaired
learning and memory [168]. Considering these early preclinical and at times inconsistent
findings on IS and brain disorders, future research focusing on microbiome-derived IS
and its participation in neurodegenerative processes might enlighten this complicated and
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emerging subject. In a dementia-prone mice model, faecal metabolites seemed to differenti-
ate from HC through higher levels of the amino acids ornithine and Tyr, which might excite
further research, considering Tyr’s role as precursor for several crucial neurotransmitters
(norepinephrine, epinephrine and DA) as well as for the uremic toxin p-cresol. Moreover,
ornithine has shown protective effects in neurotoxic ammonia [114,169], though it remains
to be determined whether bacterial metabolism is involved. Nevertheless, these reports
overall suggest gut microbial modulated AAA metabolites as potential components of the
complex and emerging field discussing the influence of GBA in AD.
Parkinson’s Disease
The analysis of gut microbial Trp metabolism in several databases of PD by Kaur
et al. [135] detected enriched indole pathways and three of its producers to be differentially
abundant in PD, namely Alistipes, Akkermansia and Porphyromonas. Concomitantly, enriched
IAA production pathways in combination with increased Lactobacillus and Staphylococcus
abundances were measured. Interestingly, distinct alterations of kynurenine and quinoli-
nate pathways were undetectable, unlike in other neuropsychiatric disorders like ASD [135].
Congruously to these activated production pathways of IAA, increased IAA urinary levels
were reported in patients with idiopathic PD [170,171] (Table 6). However, decreased
serum IAA were observed in two cohorts of Japanese patients with idiopathic and familial
PARK2-mutated PD [172,173], thus showing some inconsistencies across human studies.
Some gut bacteria capable of generating IAA are Klebsiella, Ralstonia, Staphylococcus, Bacillus,
Clostridia, Bacteroides and Escherichia [135,174] (Table 4). Interestingly, IAA was previously
mentioned to suppress pro-inflammatory cytokine production by macrophages and act on
the aryl hydrogen receptor (AHR) [109]. IAA was also able to attenuate neuroinflammation
in LPS-stimulated BV2 microglia in vitro [175]. Overall, these findings point towards a
probable role of altered gut microbial production of IAA in neuroinflammatory processes in
PD, even if further investigations need to disentangle the complexities between gut-derived
IAA and PD.
The previously mentioned metabolite and uremic toxin p-cresol (or its hepatically
sulfonated form p-cresol sulphate) in ASD [142] is generated through intestinal bacte-
rial Tyr metabolization [134], with especially strong producers within Coriobacteriaceae
and Clostridium clusters XI and XIVa [137]. P-cresol sulphate has been previously as-
sociated with neurological impairments in chronic kidney disease [162]. Moreover, two
recent studies reported significantly higher p-cresol sulphate levels in the CSF (yet not
in plasma) from PD patients compared to samples from HC [163,176] (Table 6). Addi-
tionally, higher CSF to plasma ratios in PD was observed in one study, suggesting that
individuals with PD accumulate more p-cresol sulphate in the brain than their healthy
counterparts [163,176]. These findings support the relevance of a perturbed BBB allowing
the increased permeation of putative neurotoxic microbial metabolites from circulation
to the brain in PD [165]. Moreover, p-cresol sulphate levels in CSF associated with the
presence of motor fluctuations in PD patients, suggesting a correlative connection with
disease progression [163]. This is supported by the fact that p-cresol is a known inhibitor
of dopamine–beta-hydroxylase [177], the enzyme facilitating the conversion from DA to
norepinephrine. Therefore, alterations in the p-cresol production of the microbiome, as well
as the gut bacterial impact on BBB integrity, might regulate neurotransmitter metabolism in
the brain. Cirstea et al. [132] have recently provided further evidence that associates altered
gut microbial metabolism, disturbed gut function (constipation and IBS) and PD. Com-
pared to HC, PD patients harboured decreased levels of common BA-producing Clostridia,
including some Lachnospiraceae genera (Roseburia, Coprococcus) and Faecalibacterium), as
well as enriched bacterial clusters associated with p-cresol and phenylacetylglutamine
production (Christensenellaceae, Ruminococca, Akkermansia, Oscillospira, Mogibacteriaceae).
Moreover, increased serum levels of p-cresol and phenylacetylglutamine were measured,
showing positive correlations with the presence of PD, as well as the severity of gut dys-
function. Therefore, a gut microbiome shift from BA producers to microbes generating
Nutrients 2021, 13, 732 21 of 40
AAMs such as p-cresol and phenylacetylglutamine might influence symptoms of intestinal
dysfunction, as well as altered circulating metabolites in patients with PD.
Manganese (Mn) has been shown to evoke neurodegenerative processes when accumu-
lated in the brain in the context of PD [178,179]. Recent findings discovered Mn exposure to
alter gut bacterial genes involved in amino acid and neurotransmitter metabolism (GABA,
glycine, glutamate, Trp, Phe) in a mice model, thus giving rise to the novel proposition of
gut bacterial involvement in manganese-associated neurotoxicity [180].
These findings overall suggest that members from the Clostridia class seem to be im-
plicated in the production of AAA metabolites (phenolic and indole derivatives) associated
with neurodegenerative disorders. Since Clostridia are also known as key BA producers
of the human gut [73], and as the chapters above have discussed, a probable beneficial
connection between BA and brain diseases, further investigations in Clostridia-derived
metabolites and various brain diseases seem warranted to elucidate the relevance of these
bacteria. Furthermore, our collected data on indole and indole derivatives show correla-
tions with various brain disorders (autism, anxiety, PD) that are often accompanied with
gut issues [36,110,132,181].
4.1.4. AAMs and Autoimmune Diseases of the Brain
As mentioned above, bacterial production of indole from dietary Trp might be in-
volved in perturbed brain functions. The extensive study by Rothhammer et al. [182]
has suggested, that in combination with type I interferons (IFN-Is), gut bacterial-derived
metabolites might suppress neuroinflammation through agonistic effects on the aryl hy-
drogen receptor (AHR) on astrocytes (Figure 3). Serum levels of the AHR agonists indole,
indoxyl-(3-)sulphate (IS), IPA and indole-3-aldehyde were found to be lower in patients
with MS than in HC (Table 6). Furthermore, experiments conducted in EAE mice models
of MS uncovered that depleted dietary Trp exacerbated disease, while the administra-
tion of the AHR agonists IS, IPA or indole-3-aldehyde reduced disease burden [182]. IS
specifically was further shown to cross the BBB and to stimulate AHR on astrocytes. Not
unrelatedly, another bacterial indole derivative, IAA, was able to attenuate neuroinflam-
mation in LPS-stimulated BV2 microglia in vitro [175], which underlines the hypothesis,
that bacterial-derived indoles might benefit neuroinflammatory processes by activating
the AHR on brain cells. It might further be worth noting that the Trp metabolite and
indole derivative IPA was shown to cross the BBB and to ameliorate harmful reactive
oxygen species (ROS) in the brain as a neuroprotectant [135]. Described gut genera capable
of generating IPA are few and belong to the Firmicutes phyla, namely Clostridium, Pep-
tostreptococcus, Escherichia and Proteus [134,135] (Table 4). Therefore, the presence of these
IPA-producing genera may indicate beneficial anti-oxidative properties for brain function.
Interestingly, p-cresol producing Clostridiales (including Lachnospiraceae and Ru-
minococcae families), appeared to be abundant in MS patients’ microbiomes [79,183],
which might potentially lead to similar detrimental effects on the CNS as discussed in the
chapters on ASD and PD, though no reports on elevated p-cresol in MS patients exist as
of now. The only MS study in humans to investigate the faecal metabolome, as far as our
literature search was able to capture, provided no relevant findings on non-SCFA bacterial
metabolites [29,81]. Future research is encouraged to further develop and confirm these
initial findings by conducting metabolomic, gut taxonomical and metagenomic tests in the
faecal samples of MS patients in order to look for correlations with bacterial metabolites
beyond SCFAs.
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Table 4. Gut-residing bacteria found to correlate with the production of amino acid metabolites (AAMs).
AAM Taxa Study
Taurine Alistipes HGB5, Alistipes finegoldii, Bacteroides xylanisolvens [45]
GABA Bifidobacterium, Bacteroides, Lactobacillus; Lactobacillus brevis [41,97]
GABA, lactate E. coli HT115-strain [144]
Serotonin Candida, Streptococcus, Escherichia, Enterococcus, Pseudomonas [135,184]
Serotonin, dopamine, norepinephrine Streptococcus, Enterococcus, Escherichia [135]
Serotonin, dopamine Clostridiales incertae sedis [150]
Norepinephrine Escherichia, Bacillus, Saccharomyces [184]
Dopamine Bacillus [184]
Acetylcholine Lactobacillus [184]
4EPS, p-cresol (sulphate) Clostridium [36,140,142]







Christensenella, Candidatus arthromitus [150]
“TRYP6”




Quinolinate, indole, IAA, IPA, tryptamine Clostridium [135]
Kynurenine, quinolinate, indole, IAA, IPA Burkholderia [135]
Kynurenine, quinolinate, IAA, tryptamine Streptomyces, Pseudomonas, Bacillus [135]
IAA Bacillus, Klebsiella, Ralstonia, Staphylococcus [135]
Indole Bacteroides, Citrobacter, Clostridium_XIX, Desulfitobacterium,Edwardsiella, Escherichia, Fusobacterium, Providencia, Shigella [135]




IPA Clostridium, Escherichia, Proteus [135]
Kynurenine Pseudomonas, Bacillus, Burkholderia, Streptomyces [135]
Quinolinate Klebsiella, Bacillus, Burkholderia [135]





GABA = gamma-aminobutyric acid; TRYP6 = six Trp metabolism pathways generating the neuroactive metabolites in brackets (“);
4EPS = 4-ethylphenylsulfate; IAA = indole-acetic acid; IPA = indole-propionic acid. References are listed as numbers in brackets.
Table 5. Sixteen faecal metabolites with significant correlation in rats with induced depression (adjusted from Yu et al. [150]).
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Table 5. Cont.




Faecal levels in depressed rats compared to healthy control group: ↑ = upregulated; ↓ = downregulated. Rows marked in blue have a p-value
of p < 0.01, whereas rows in white reached p < 0.05. MG = monoacylglyceride; PE = phosphatidylethanolamine; PS = phosphatidylserine
Table 6. Bacterial AAMs correlated with brain diseases or the progression of brain diseases.
Disease Amino Acid Metabolites Sample and Literature p-Values
ASD
P-cresol
- f [42] p = 0.884
↑ f [39], f [41], * s/p [36], u [138,139]
p < 0.05, p = 0.04,
p < 0.05, p < 0.05,
p < 0.05
IAA, indolyl lactate ↑
u [143]
p < 0.001
IS ↑ p < 0.05
Indoles (indole, 3-methylindole) ↑ f [39] p < 0.05
Serotonin, GABA ↑ * s/p [36] p < 0.05




↑ * u [36] p < 0.05
PD
P-cresol ↑ * c [109], c [176], s [132], ccapa [163]
p < 0.05, p = 0.0002,
p = 0.0028, p < 0.05
IAA
↓ s [172,173], * s [109]
p = 0.0083, p = 0.0258,
p < 0.05
↑ * cp [109], u [170,171] p < 0.05, p b, p < 0.001
Indole ↑ * cp [109] p < 0.05
IS ↑ c a [163] p < 0.05
Catechol sulphate, hippuric acid,




↓ * s [109] p < 0.05
Phenylactate, 3-(4-hydroxyphenyl)lactate ↑ * s [109] p < 0.05
3-(4-hydroxyphenyl)acetic acid, tryptamine,
phenylacetic acid, aminobenzoic acid,
hydroxybenzoic acid
↑ u [170,171] p < 0.05
Phenylacetylglutamine ↑ s [132] p = 0.004
Quinic acid ↑ * c [109] p < 0.05
Trimethylamine, threonate ↓ * p [109] p < 0.05
Benzoic acid, 3-(4-hydroxyphenyl)acetic acid ↓ * cp [109] p < 0.05
MS Aryl hydrocarbon receptor agonists ↓ s [182] p < 0.05
This table shows the differences of AAM levels of various sample materials from human patients compared to healthy controls. p-values are
listed in the last column while the significant date is written in bold letters. ↑ symbolizes increased, ↓ decreased, whereas—symbolizes no
change in the metabolite levels found in cohorts with the specific disease. Sample material is noted as f = faecal; s = serum; c = cerebrospinal
fluid; p = plasma; u = urine; s/p = blood samples with the associated reference as numbers in brackets. References noted with “*” are
sourced from reviews. p-values < 0.05 are marked in bold letters. a correlated with progression of disease. b (p = 0.00364 PD in early stage
of disease, p < 0.001 PD in mid-stage, p = 0.056 PD in late-stage compared to HC). (For example: ccapa = altered cerebrospinal fluid sample,
and altered cerebrospinal as well as plasma samples which correlate with disease progression). IAA = indoleacetic acid; IS = indoxyl
sulphate; GABA = gamma-aminobutyric acid; IPA = indole propionic acid.
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4.2. Other Metabolites
4.2.1. Trimethylamine N Oxide (TMAO)
The gut bacterial fermentation of dietary L-carnitine and phosphatidylcholine, which
are abundant in red meat, produces trimethylamine (TMA). The following hepatic oxidiza-
tion by flavin-containing monooxygenase 1 and 3 (FMO1 and FMO3) produces trimethy-
lamine N oxide (TMAO), a metabolite frequently linked to increased risk of cardiovascular,
metabolic and cerebrovascular disease, whether as a mediating factor, marker or by-
stander of disease [185–188]. Recent studies have detected TMAO in human cerebrospinal
fluid (CSF), thus establishing its presence in the brain beyond the cerebrovascular sys-
tem [188,189]. It is to mention that TMAO plasma levels are subject to factors besides gut
microbiome composition, namely diet and liver enzyme activity. It is presently unclear how
much circulating levels in the CSF depend on the de novo biosynthesis of TMAO in the
brain. Recent studies have shown, however, strong correlations between CSF and plasma
levels, suggesting that TMAO brain-levels largely derive from the availability in blood,
thus supporting the theory of peripheral TMAO reaching the CNS [163]. Interestingly,
TMAO plasma levels were found to be significantly higher in elderly humans as well
as in aged mice compared to their respective younger groups [190–193]. This would be
coherent with recently reported associations between shifts in gut microbiota and presence
of neurodegenerative disorders [89,110,194].
By assessing TMAO CSF levels in volunteers with AD dementia, mild cognitive
impairment (MCI) and healthy controls (HC), as well as correlations between TMAO
CSF levels and biomarkers of AD and neurodegeneration, Vogt et al. [188] have reported
the potential involvement of TMAO in AD. They found significantly higher CSF levels
of TMAO in the AD and MCI groups compared to HC, with no differences between
AD and MCI [195], all while controlling for age, sex and APOE ε4 genotype. Moreover,
they discovered CSF TMAO levels to be significantly correlated with AD biomarkers that
indicate a connection to tau pathology and axonal injury. Congruously, a different study
observed plasma TMAO levels to be inversely correlated with cognitive functions (working
memory, episodic memory and fluid cognition) in middle-aged to older adults [193].
Conversely, a recent study reported no differences in TMAO levels between CSF
samples from PD patients and HCs. Nevertheless, significant TMAO elevations were
detected in PD patients with motor fluctuations compared to those without (Table 7), thus
pointing to a role of TMAO in disease progression [163].
Table 7. Other bacterial metabolites correlated with brain diseases or progression in humans.
Disease Metabolite Change Literature
AD TMAO ↑ c [188]
MCI TMAO ↑ c [188]
PD TMAO ↑ cappa [163]
ASD Isopropanol ↑ f [41]
AD = Alzheimer’s disease; MCI = mild cognitive impairment; PD = Parkinson’s disease, ASD = autism spectrum
disorder; TMAO = trimethylamine N oxide, a correlated with the progression of disease. Significance of data is
p ≤ 0.05. ↑ symbolizes increased metabolite levels found in cohorts with the specific disease compared to healthy
controls. Sample material is noted as f = faecal, c = cerebrospinal fluid, p = plasma sample with the associated
reference as numbers in brackets.
Researchers have previously mentioned shared pathological arteriosclerotic and in-
flammatory mechanisms between cardiovascular and dementia-associated cerebrovascular
diseases [93]. Literature on vascular cognitive impairment (VCI), a broad definition encom-
passing cognitive disorders with associations to any kind of cerebral vascular brain injury,
further proposed that risk factors for VCI, including hypertension, hypercholesterolemia,
diabetes mellitus, atrial fibrillation and others, might overlap the ones for AD [196]. Ad-
ditionally, results in genetically modified mice previously indicated TMAO to cause the
progression of atherosclerosis, a risk factor for dementia [195,197]. TMAO was further
implicated with decreased reverse cholesterol transport in mice [198] and enhanced platelet
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hyperreactivity and thrombosis risk in mice and human subjects [199]. This might suggest
a vascular aspect of the mechanism by which this bacterial metabolite might take part in
the pathophysiology of AD. However, as Vogt et al. [188] found, differences in TMAO
levels between healthy controls, MCI and AD groups were independent from traditional
cardiovascular disease risk factors such as body mass index, blood pressure, cholesterol
and fasting glucose. Positive associations between TMAO levels and biomarkers for AD
and neurodegeneration were also further controlled for peripheral vascular disease risks
factors, thus implying that TMAO might affect neurodegeneration by other means than
vascular mechanisms. Overall, whether and to what extent TMAO might influence AD by
the promotion of vascular disfunction is still to be determined at this point in time.
In studies investigating TMAO’s involvement in other mechanisms of neurological
diseases, this bacterial metabolite was proposed to weaken the BBB by downregulating
tight junction proteins in humans [200]. After reaching the CNS, TMAO was shown
to promote neuronal senescence in the hippocampus and cognitive impairment in mice
by increasing oxidative stress, disturbing mitochondrial dysfunction and inhibiting the
mammalian target of rapamycin (mTOR) signalling, which increased synaptic damage
as well as reduced synaptic plasticity-related proteins [190]. A study with the APP/PS1
transgenic mice model of AD indicated higher TMAO-levels in plasma to be associated
with cognitive and pathological deterioration, while treatment with the TMA formation
inhibitor 3,3-Dimethyl-1-butanol (DMB) alleviated cognitive deterioration and defective
synaptic plasticity [191]. Furthermore, DMB treatment managed to reduce hippocampal
neuroinflammation and AD-associated pathologies like Aβ42, β-secretase and βCTF (β-
secretase-cleaved C-terminal fragment) levels in APP/PS1 mice [191]. Similarly, a different
transgenic mouse model of AD (3x Tg-AD) displayed significantly elevated plasma and
brain TMAO levels in comparison to healthy controls in a recent study by Govindarajulu
et al. [192]. They further incubated hippocampal brain slices of wild-type mice with
TMAO and found deficits in synaptic plasticity, impaired synaptic transmission, altered
presynaptic and reduced postsynaptic glutamatergic receptor units, as well as induced
endoplasmatic reticulum (ER)-mediated protein kinase RNA-like endoplasmic reticulum
kinase (PERK) pathway [192]. Another study has further indicated TMAO to impair
cognitive function by promoting neuroinflammation and astrocyte activation in mice [193].
In addition to the association between TMAO levels and neuroinflammation and astrocyte
activation in older mice, TMAO supplementation in young mice for six months exhibited a
decline in memory and learning (assessed through the novel object recognition test) and
indeed, elevated markers for neuroinflammation and astrocyte activation. Furthermore,
human astrocyte cultures incubated with TMAO showed altered cellular morphology
and markers indicating astrocyte activation, thus proposing a direct effect of TMAO on
astrocytes [193]. Overall, all of these preclinical findings suggest that TMAO may provoke
cognitive impairment by promoting neuroinflammation, AD-related amyloid formation,
oxidative stress, as well as deficits in synaptic plasticity and function by promoting ER
stress-mediated PERK signalling pathways.
Additionally, an in silico study detected significant correlations between TMAO-
related genes and AD biomarkers in nine potential genetic pathways involved in both,
that might underline the proposition for TMAO as a strong biomarker for AD [201].
Those nine pathways include in no specific order: the metabolism of proteins; immune
system; adaptive immune system; Alzheimer’s disease; axon guidance; amyotrophic lateral
sclerosis (ALS); erythropoietin-producing human hepatocellular receptor A (EPHA) and
B (EPHB) forward signalling and metabolism of lipids and lipoproteins. These findings
might be used as groundwork for investigations of specific pathways that might elucidate
a diet-microbial metabolite–brain disease axis.
Curiously, studies in mice and in vitro models reported disease-mediating as well as
protective mechanisms by TMAO on processes in neurodegenerative disorders such as a
reduction in amyloid aggregation in AD and PD, thus providing a new potential therapeutic
target [22,200]. However, more congruous study results have been reviewed and reported
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on the pro-inflammatory effects of increased TMAO plasma concentrations [200]. These
reports underline the need for further studies on TMAO and its combined effects on
enhanced circulating pro-inflammatory mediators that can potentially cross a TMAO-
induced disturbed BBB to a greater extent, and therefore promote the aforementioned
neuroinflammatory and neurodegenerative effects in the brain.
Some gut bacteria found to be significantly associated with enhanced plasma TMAO
were the genera Prevotella, Mitsuokella, Fusobacterium, Desulfovibrio, Methanobrevibacter
smithii, and some from the Lachnospiraceae and Ruminococcaceae families [186] (Table 8).
Three of those genera belong to the Bacteroidetes and six to the Firmicutes class, con-
gruous with a recent study in dementia [93] that showed a significantly higher Firmi-
cutes/Bacteroidetes ratios in demented individuals with MRI-detected silent lacunar in-
farctions, as well as strong correlations between dementia and low counts of Bacteroides
along with higher counts of ‘other bacteria’. Additional sources have reported the fol-
lowing TMA-producing genera: Anaerococcus, Clostridium, Escherichia, Proteus, Providencia
and Edwardsiella [22]. Overall, future work is strongly advised to address and investigate
TMAO brain levels and any correlations with the gut microbiome.
Carnitine Analogues
Given that gut metabolites related to carnitine such as TMAO affect the GBA, re-
searchers have recently discovered two new potentially brain active metabolites, namely
the carnitine analogues 3-methyl-4-(trimethylammonio)butanoate (3M4-TMAB) and 4-
(trimethylammonio)pentanoate (4-TMAP) [202]. These compounds are generated by gut
bacteria from the family Lachnospiraceae (Clostridiales symbosium and clostridioforme) (Table
8) and were absent in both the gut and brain of GF mice but present in controls, thus sug-
gesting that gut microbiota may be responsible for their presence in the brain. Importantly,
these compounds were found in identical regions of white matter of the brain as carnitine
and showed an inhibition of carnitine-mediated fatty acid oxidation (FAO) in a murine
cell culture model of CNS white matter [202]. FAO is crucial for neuronal energy home-
ostasis, and inborn errors of this system may link faulty neuronal stem cell self-renewal to
ASD [203,204]. Considering these findings and that increased abundance of Clostridia have
been linked to ASD and other neurodevelopmental disorders [205], faulty FAO promoted
by bacterial metabolites might be an important topic to explore in the future.
4.2.2. Polyphenolic Metabolites
Polyphenols derived from dietary sources are metabolized by human gut microbes
to phenolic acids. Research has shown gut microbial metabolites of dietary polyphenols
to accumulate in brain tissue and to modulate α-synuclein misfolding, aggregation and
neurotoxicity in vitro and in an animal models [206]. Among those metabolites were
3-hydroxybenzoic acid (3-HBA), 3-(3-hydroxyphenyl)propionic acid (3-HPPA) and 3,4-
dihydroxybenzoic acid (3,4-diHBA). Further investigations led to the detection of B. ovatus
as a producer of the aforementioned metabolites that were converted from the dietary
polyphenols (+)-catechin (C) and (−)-epicatechin (EC). C/EC-independent production
of 3,4-diHBA, 3-HBA and dihydrocaffeic acid (DHCA), a circulating anti-inflammatory
phenolic acid, also occurred through B. ovatus, E. lenta and E. coli (Table 8). In earlier stud-
ies, 3-HPPA and 3-HBA were shown to ameliorate Aβ-peptide misfolding [207], therefore
underlining the potential of bacterial polyphenolic metabolites to protect from neuro-
toxic protein-aggregation and neurodegenerative disorders like AD and PD. Additional
gut bacterial metabolism-derived polyphenols, particularly enerolactone and enterodiol,
aryl-γ-valerolactone metabolites and urolithin A/B, exhibit polyphenolic neuroprotective
properties [208]. Two studies have further summarized mechanisms by which brain func-
tion could be influenced by bioactive microbe-derived metabolites of polyphenols [209,210].
Direct neuroprotective impacts include modulating neuronal receptors, antioxidation, anti-
inflammation and overall neuroprotective effects. Indirect mechanisms encompass the
modulation of gut microbial homeostasis by supporting beneficial bacteria while decreas-
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ing pathogens, as well as improving cerebrovascular health by increased nitrogen oxide
levels and vasodilatory response. Limits of the summarized findings were put by their
in vitro and ex vivo-based designs.
The ability to cross the BBB is crucial for metabolites to exert neuroactive properties
and ten microbe-derived polyphenolic metabolites were found to be capable of distributing
in rat brains after intravenous administration [211]: 4-hydroxyhippuric acid, homovanillic
acid, 4-hydroxybenzoic acid, vanillic acid, 3-HPPA, trans-ferulic acid, caffeic acid, gallic
acid, 3,4-dihydroxyphenyl acetic acid and urolithin B. Taken together, the neuroactive
potential of bioactive gut microbe-derived metabolites of dietary polyphenols is promising
but the mode of action of these metabolites need further in depth elucidation.
Phenolic Compounds
Ferulic acid (FA), a phenolic compound, has been the focus of a handful of studies
researching the GBA and has been proposed a role in cognitive development and neuropro-
tection. Sources of ferulic acid are plants and seeds in the human diet, as well as from gut
microbial biosynthesis from dietary cyanidin, catechin and epicatechin. Some beneficial
properties of FA are protection from oxidative neurological damage by ROS scavenging,
neural stem cell stimulation, and the direct inhibition of Aβ aggregation [8,212–214].
Dysfunctions in Pavlovian fear extinction learning are involved in anxiety and fear-
associated neuropsychiatric disorders such as PTSD [215,216]. Recently, four bacterial
metabolites, of which three were phenolic compounds (phenyl sulphate, pyrocatechol
sulphate and 3-(3-sulfooxyphenyl)propanoic acid), have been shown to be significantly
decreased in CSF, serum and faecal samples of GF or antibiotic treated mice showing
defective fear extinction learning. Further investigations discovered alterations of gene
expressions in the medial prefrontal cortex, immature-like microglia, as well as perturbed
structural and functional changes in neurons involved in learning processes [168].
4.2.3. Bacterial Amyloid Proteins
Amyloid proteins produced by bacteria have been an emerging subject of interest
in the study of pathophysiology in PD [109]. It was reported that bacterial amyloid
proteins, such as curli from E. coli, could induce the formation of human amyloid aggregates
by cross-seeding in a prion-like fashion, as well as promote inflammatory processes by
molecular mimicry [217]. The mechanism of cross-seeding was previously shown by curli-
induced serum amyloid A amyloidosis in mice [218]. This was further supported by a
hypothesis that the phenomenon of protein misfolding in neurodegenerative diseases might
originate from the gut, possibly via bidirectional vagal fibres bypassing the circulatory
system [108]. It is important to note that vagotomy has been associated with a lower risk
for PD [219] and a delayed αSyn dissemination when nervous structures connecting the
gut to the brain are severed [220]. Findings of αSyn aggregates in regions beyond the
brain, such as the enteric nervous system and olfactory bulb, point to the phenomenon that
the majority of PD patients experience gastrointestinal and olfactory dysfunctions long
before their diagnosis [221]. Interestingly, hyposmia has been associated with cognitive
decline, even in the context of AD [222]. A recent study observed that mice with αSyn
overexpression developed PD-like pathological traits after inoculation with curli-producing
E. coli. These mice displayed αSyn-aggregates in brain and gut tissues, as well as disturbed
motor and intestinal functions [223]. Furthermore, prior research reported significantly
increased amounts of αSyn aggregates in aged Fischer 344 rat brains and in Caenorhabditis
elegans after oral inoculation with curli-producing E. coli in comparison with subjects
colonized with identical strains lacking curli production. Moreover, exposure to curli-
producing E. coli stimulated immune activity in rat brains, represented by enhanced
neuroinflammatory markers, such as upregulated Toll-like receptor 2 (TLR2), interleukin
6, tissue necrosis factor, microgliosis and astrogliosis [224]. The similar immune response
pathways to bacterial amyloids by pathogen-associated molecular pattern recognition, and
the response to misfolded endogenous amyloids like αSyn and Aβ is intriguing. This
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illustrates the possibility that gut bacterial amyloids could prime the immune system for
a neuroinflammatory response to cerebral amyloid deposits, thus leading to enhanced
neuroinflammation and degeneration [217].
Species reported for curli-production are from the family Enterobacteriaceae, including
E. coli, Salmonella typhimurium, Citrobacter spcc., Cronobacter sakazakii and Proteus mirabilis.
This was recently deemed as conspicuous by researchers that observed enriched Enterobac-
teriaceae spp. in 31% of PD studies, as well as previous associations between P. mirabilis and
a PD mouse model [109]. Other residents of the human gut were also reported to generate
extracellular amyloids, namely Streptococcus, Staphylococcus, Mycobacteria, Klebsiella and
Bacillus spp. [217]. Overall, these studies provide a hypothesis that bacterial amyloids could
be key players in the pathogenesis of neurodegenerative diseases like PD and AD, with
data pointing to their effects on amyloid aggregation and on enhanced immunoreactions
in the CNS. This subject even motivated Friedland et al. [217] to propose the new term
“MAPRANOSIS—the process of microbiota-associated proteopathy and neuroinflamma-
tion”. However, some preclinical studies have implicated bacterial amyloids with increased
clearance and decreased neuroinflammation by means of activating microglia through the
receptor TREM2 [91]. Similarly, toll-like receptors 2 and 4 (TLRs) have shown contradicting
effects on amyloid-related neurotoxicity and clearance through microglial activation [225].
It is difficult to draw definite conclusions regarding the effect of gut bacterial amyloids on
AD and PD. Nevertheless, current data are strongly pointing to an existing connection.
Yang et al. [226] recently conducted the first study to observe implications of gut
dysbiosis and faecal metabolic changes in mice with prions disease, thus providing the
base for a new area of research in brain diseases with links to the gut microbiome. Of the
previously mentioned metabolites, SCFAs and Trp were decreased, while Tyr increased in
mice with prions disease. Furthermore, the microbiome of prion-infected mice harboured
distinct compositions from HC, namely enriched Lactobacillaceae, Helicobacteraceae and
decreased Prevotellaceae and Ruminococcaceae. Additionally, newly observed altered
faecal metabolites consisted of various glycerophospholipids, three secondary bile acids
and the toxic avermectin A2b. However, further research should investigate if these
compounds are derived from gut bacterial metabolism and whether they are biomarkers
or mediators of disease.
Table 8. Gut-residing bacteria found to correlate with the production of other metabolites.
Other Metabolites Taxa Study
TMA(O)
Prevotella, Mitsuokella, Fusobacterium, Desulfovibrio, Methanobrevibacter
smithii; some from Lachnospiraceae and Ruminococcaceae
[186]
TMA Anaerococcus, Clostridium, Escherichia, Proteus, Providencia, Edwardsiella [22]
curli
Enterobacteriaceae (E. coli, Salmonella typhimurium, Citrobacter freundii,
Cronobacter sakazakii, Proteus mirabilis)
[109]
curli E. coli [224]
curli Streptococcus, Staphylococcus, Mycobacteria, Klebsiella, Bacillus [217]
Nicotinamide Akkermansia muciniphila [227]
3-HBA, 3,4diHBA, DHCA Bacteroides ovatus [206]
3-methyl-4-(trimethylammonio)butanoate,
4-(trimethylammonio)pentanoate
Lachnospiraceae (Clostridiales): C.clostridioforme, C.symbosium [202]
TMA(O) = trimethylamine N oxide; TMA = trimethylamine; 3-HBA = 3-hydroxybenzoic acid; 3,4-diHBA = 3,4-dihydroxybenzoic acid;
DHCA = dihydrocaffeic acid. References are represented by numbers in brackets.
5. Discussion and Conclusions
Our collected data highlight the fact that research into GBA and the precise role of
bacterial metabolites as key contributors is still in its infancy. The majority of studies were
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conducted in preclinical animal or cell models and only a limited number of human studies
are contributing to the current knowledge.
Only a handful of human studies of brain diseases reported faecal SCFAs levels,
making it difficult to draw definitive conclusions. Our literature search captured five
studies in ASD, two in affective disorders, two in MS, one in PD and none in AD as of this
point in time. Nevertheless, an overall decrease in faecal SCFA levels in ASD, affective
disorders, MS and PD is apparent (Table 1). Importantly, an increase in one SCFA may
be levelled out by the decrease in another SCFA in the same study. AA and PA were
reported to be increased in faecal samples [39,42] in two studies, while BA was increased
in one [42]. Furthermore, one study observed no significant changes across all SCFAs
in ASD [41]. Therefore, it remains to be determined by in-depth studies of the human
intestinal metabolome, whether distinct patterns of SCFA levels are present and relevant in
different brain diseases.
Based on preclinical findings on how SCFA might impact the brain, the overall assump-
tion points to a beneficial role. The non-exhaustive list of reported effects includes improved
gut barrier and BBB integrity [19–22] and an overall shift towards anti-inflammatory pro-
cesses [13,28,29,74,75,91]. As HDACI, SCFAs can epigenetically modulate the maturation of
brain cells [28,84,87], enhance gene expression for enzymes relevant in catecholamine pro-
duction [23] and even shift the balance of the immune system towards anti-inflammatory
Treg cells and away from pro-inflammatory Th1 and Th17 cells [13,81,83]. Inflammatory
processes are known to be involved in MS and to take part in neurodegenerative diseases.
As SCFA levels tend to be decreased in most neurodegenerative diseases (Table 1), we
might assume that a perturbed gut microbiome might lead to impaired SCFA production of
gut bacteria, which might then deplete the beneficial anti-inflammatory effects on the CNS.
Regarding non-SCFA bacterial metabolites, p-cresol has yielded the most human data
across studies. It is also the only metabolite with measurements in faecal samples that
correlated with brain disease, namely in patients with ASD. Taken all results together
(Table 6), p-cresol is significantly increased in faecal, urinary and blood samples of ASD, as
well in the CSF and serum of PD patients. CSF and plasma levels of p-cresol have moreover
shown to be correlated with the severity of PD [163]. This, and preclinical studies in mice
models implicating p-cresol with detrimental effects on the CNS [140,141], seem to be in
line with elevated levels in ASD and PD. The notion of involvements of p-cresol in ASD is
supported by the finding that 4EPS, a metabolite with structural similarities to p-cresol,
induces ASD-behaviour in mice.
Alterations in Trp metabolism were observed in human studies in ASD, PD and
MS. Significant assessments of Trp metabolites such as indole and indole derivatives are
mainly from non-faecal samples and have shown an overall increase in ASD, a decrease
in MS and inconsistent results in PD (Table 6). Nevertheless, it is important to mention
that two PD studies showed indole and indole derivatives to be increased in CSF [109,
163], a compartment closely connected to brain tissue. Furthermore, metagenomic tests
concluded that overall Trp metabolism pathways are enriched in the gut microbiome of
ASD patient cohorts, and that indole pathways are enhanced in PD microbiomes [135].
These metagenomic findings and the several reports on metabolite levels in patients seem to
indicate the presence of perturbed and enriched Trp metabolism in ASD and PD. Naturally,
the lack of studies testing for faecal metabolites in humans, as well as the inconsistencies
within results in PD stress the limitation to unequivocally determine distinct patterns by
which our gut bacteria alter Trp metabolism in various brain diseases.
Several probable mechanisms by which Trp metabolites might exert their impact were
identified. Preclinical studies have indicated that indole and its derivatives (indole, IS, IPA,
indole-3-aldehyde, IAA) might actually be able to limit neuroinflammation by acting as
agonists on the AHR [109,182] (Figure 3). Furthermore, a shift in Trp-metabolism away
from 5-HT production might partly explain the worsening of disease in individuals who
are responsive to treatment with selective serotonin-reuptake inhibitors (SSRIs) [146,147].
Thus, a decrease in Trp availability might be connected to brain diseases, which is further
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exemplified by Trp-depletion experiments in depressed human cohorts and mice models of
MS [146,147,182]. It might further be of interest that IPA was reported to ameliorate toxic
ROS activity in the brain [135]. On the other hand, IS has induced oxidative stress in animal
and in vitro studies [163,164], as well as displayed potential neurotoxic effects in mice
through perturbed microglial and astrocyte function [165]. Moreover, an overproduction
of indole was associated with anxiety and depression levels in rats [155]. Taken together,
these results imply that alterations in the gut bacterial metabolism of AAA, whether it is
Tyr-derived p-cresol or Trp-derived indole metabolites, could contribute to brain diseases.
The question as to whether gut bacterial amyloids like curli might contribute to
or alleviate diseases with an accumulation and aggregation of misfolded proteins and
neuroinflammation, cannot be unequivocally answered yet. Nevertheless, the current
evidence on bacterial amyloids implies that there might be more to bacterial metabolites
with connections to the brain beyond SCFAs and AAM.
The majority of evidence presented here is derived from preclinical studies, such as
in vivo studies in transgenic animals, in germ-free animals or animals exposed to early-
life alterations of the gut microbiota including pathogens, probiotics, or antibiotics. The
validity of drawing decisive conclusions for the human physiology from animal studies
is therefore conceivably limited. Moreover, the information on taxonomical alterations
and associations to metabolites and diseases is non-exhaustive since this study focused
on bacterial metabolites. The objective was to assess bacterial metabolites independently
as probable determinants of disease, thus shifting the focus away from their producers.
The need for further work in deciphering the vast and intricate correlations between
gut microbial communities, faecal metabolites and the presence of brain dysfunction, is
definitely acknowledged and deemed as necessary.
Results regarding the potential protective or aggravating role of bacterial metabo-
lite groups on brain diseases are still few and require additional confirmation. A final
assessment of the importance of faecal metabolomic changes in brain diseases, however,
is problematic as of now. The difficulties lie in the heterogeneity of disease manifesta-
tions and varying technological methods to assess varying sample sources. Furthermore,
confounders like gender, genetics, dietary factors, medication and lifestyle, as well as
subtypes of bacterial species, might contribute to insignificant or falsified results. Therefore,
additional independent research applying methodical standardization is essential to en-
sure comparable and reproducible data. Determining not only taxonomical data, but also
conducting functional analyses through metagenomic and metabolomic testing of faecal
samples would crucially increase the robustness of discovered associations. This might
further develop, confirm or refute today’s initial findings on correlations between bacterial
metabolites and brain diseases. Interests lie in the discovery and unravelment of GBA
mechanisms, as well as the study of bacterial metabolites as promising key contributors
to brain diseases. Successful findings of such might be crucial in identifying aetiological
and pathophysiological processes, thus efficaciously supporting future research in novel
treatments and the prevention strategies of brain diseases.
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IPA indole propionic acid
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HC healthy controls
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163. Sankowski, B.; Księżarczyk, K.; Raćkowska, E.; Szlufik, S.; Koziorowski, D.; Giebułtowicz, J. Higher cerebrospinal fluid to plasma
ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson’s disease. Clin. Chim. Acta 2020, 501, 165–173. [CrossRef]
[PubMed]
164. Dou, L.; Jourde-Chiche, N.; Faure, V.; Cerini, C.; Berland, Y.; Dignat-George, F.; Brunet, P. The uremic solute indoxyl sulfate
induces oxidative stress in endothelial cells. J. Thromb. Haemost. 2007, 5, 1302–1308. [CrossRef] [PubMed]
165. Adesso, S.; Magnus, T.; Cuzzocrea, S.; Campolo, M.; Rissiek, B.; Paciello, O.; Autore, G.; Pinto, A.; Marzocco, S. Indoxyl Sulfate
Affects Glial Function Increasing Oxidative Stress and Neuroinflammation in Chronic Kidney Disease: Interaction between
Astrocytes and Microglia. Front. Pharm. 2017, 8, 370. [CrossRef]
166. Singh, A.; Kukreti, R.; Saso, L.; Kukreti, S. Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. Molecules 2019,
24, 1583. [CrossRef]
167. Gray, M.T.; Woulfe, J.M. Striatal blood-brain barrier permeability in Parkinson’s disease. J. Cereb. Blood Flow Metab. 2015,
35, 747–750. [CrossRef] [PubMed]
168. Chu, C.; Murdock, M.H.; Jing, D.; Won, T.H.; Chung, H.; Kressel, A.M.; Tsaava, T.; Addorisio, M.E.; Putzel, G.G.; Zhou, L.; et al.
The microbiota regulate neuronal function and fear extinction learning. Nature 2019, 574, 543–548. [CrossRef] [PubMed]
169. Zieve, L.; Lyftogt, C.; Raphael, D. Ammonia toxicity: Comparative protective effect of various arginine and ornithine derivatives,
aspartate, benzoate, and carbamyl glutamate. Metab. Brain Dis. 1986, 1, 25–35. [CrossRef]
170. Luan, H.; Liu, L.F.; Tang, Z.; Zhang, M.; Chua, K.K.; Song, J.X.; Mok, V.C.; Li, M.; Cai, Z. Comprehensive urinary metabolomic
profiling and identification of potential noninvasive marker for idiopathic Parkinson’s disease. Sci. Rep. 2015, 5, 13888. [CrossRef]
[PubMed]
171. Luan, H.; Liu, L.F.; Meng, N.; Tang, Z.; Chua, K.K.; Chen, L.L.; Song, J.X.; Mok, V.C.; Xie, L.X.; Li, M.; et al. LC-MS-based urinary
metabolite signatures in idiopathic Parkinson’s disease. J. Proteome Res. 2015, 14, 467–478. [CrossRef]
172. Hatano, T.; Saiki, S.; Okuzumi, A.; Mohney, R.P.; Hattori, N. Identification of novel biomarkers for Parkinson’s disease by
metabolomic technologies. J. Neurol. Neurosurg. Psychiatry 2016, 87, 295–301. [CrossRef]
173. Okuzumi, A.; Hatano, T.; Ueno, S.I.; Ogawa, T.; Saiki, S.; Mori, A.; Koinuma, T.; Oji, Y.; Ishikawa, K.I.; Fujimaki, M.; et al.
Metabolomics-based identification of metabolic alterations in PARK2. Ann. Clin. Transl. Neurol. 2019, 6, 525–536. [CrossRef]
174. Gao, J.; Xu, K.; Liu, H.; Liu, G.; Bai, M.; Peng, C.; Li, T.; Yin, Y. Impact of the Gut Microbiota on Intestinal Immunity Mediated by
Tryptophan Metabolism. Front. Cell. Infect. Microbiol. 2018, 8, 13. [CrossRef]
175. Kim, D.-C.; Quang, T.H.; Yoon, C.-S.; Ngan, N.T.T.; Lim, S.-I.; Lee, S.-Y.; Kim, Y.-C.; Oh, H. Anti-neuroinflammatory activities of
indole alkaloids from kanjang (Korean fermented soy source) in lipopolysaccharide-induced BV2 microglial cells. Food Chem.
2016, 213, 69–75. [CrossRef] [PubMed]
176. Willkommen, D.; Lucio, M.; Moritz, F.; Forcisi, S.; Kanawati, B.; Smirnov, K.S.; Schroeter, M.; Sigaroudi, A.; Schmitt-Kopplin, P.;
Michalke, B. Metabolomic investigations in cerebrospinal fluid of Parkinson’s disease. PLoS ONE 2018, 13, e0208752. [CrossRef]
177. Southan, C.; DeWolf, W.E., Jr.; Kruse, L.I. Inactivation of dopamine beta-hydroxylase by p-cresol: Evidence for a second, minor
site of covalent modification at tyrosine 357. Biochim. Biophys. Acta 1990, 1037, 256–258. [CrossRef]
178. Crossgrove, J.; Zheng, W. Manganese toxicity upon overexposure. NMR Biomed. 2004, 17, 544–553. [CrossRef] [PubMed]
179. Reaney, S.H.; Bench, G.; Smith, D.R. Brain accumulation and toxicity of Mn(II) and Mn(III) exposures. Toxicol. Sci. 2006,
93, 114–124. [CrossRef] [PubMed]
Nutrients 2021, 13, 732 39 of 40
180. Chi, L.; Gao, B.; Bian, X.; Tu, P.; Ru, H.; Lu, K. Manganese-induced sex-specific gut microbiome perturbations in C57BL/6 mice.
Toxicol. Appl. Pharm. 2017, 331, 142–153. [CrossRef] [PubMed]
181. Fowlie, G.; Cohen, N.; Ming, X. The Perturbance of Microbiome and Gut-Brain Axis in Autism Spectrum Disorders. Int. J. Mol.
Sci. 2018, 19, 2251. [CrossRef]
182. Rothhammer, V.; Mascanfroni, I.D.; Bunse, L.; Takenaka, M.C.; Kenison, J.E.; Mayo, L.; Chao, C.C.; Patel, B.; Yan, R.; Blain,
M.; et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system
inflammation via the aryl hydrocarbon receptor. Nat. Med. 2016, 22, 586–597. [CrossRef]
183. Cekanaviciute, E.; Yoo, B.B.; Runia, T.F.; Debelius, J.W.; Singh, S.; Nelson, C.A.; Kanner, R.; Bencosme, Y.; Lee, Y.K.; Hauser, S.L.;
et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc.
Natl. Acad. Sci. USA 2017, 114, 10713–10718. [CrossRef]
184. Mohanta, L.; Das, B.C.; Patri, M. Microbial communities modulating brain functioning and behaviors in zebrafish: A mechanistic
approach. Microb. Pathog. 2020, 145, 104251. [CrossRef]
185. Chong-Nguyen, C.; Duboc, H.; Sokol, H. The gut microbiota, a new cardiovascular risk factor? Presse Med. 2017, 46, 708–713.
[CrossRef]
186. Fu, B.C.; Hullar, M.A.J.; Randolph, T.W.; Franke, A.A.; Monroe, K.R.; Cheng, I.; Wilkens, L.R.; Shepherd, J.A.; Madeleine, M.M.;
Le Marchand, L.; et al. Associations of plasma trimethylamine N-oxide, choline, carnitine, and betaine with inflammatory and
cardiometabolic risk biomarkers and the fecal microbiome in the Multiethnic Cohort Adiposity Phenotype Study. Am. J. Clin.
Nutr. 2020, 111, 1226–1234. [CrossRef]
187. Velasquez, M.T.; Ramezani, A.; Manal, A.; Raj, D.S. Trimethylamine N-Oxide: The Good, the Bad and the Unknown. Toxins 2016,
8, 326. [CrossRef]
188. Vogt, N.M.; Romano, K.A.; Darst, B.F.; Engelman, C.D.; Johnson, S.C.; Carlsson, C.M.; Asthana, S.; Blennow, K.; Zetterberg, H.;
Bendlin, B.B.; et al. The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease. Alzheimers
Res. Ther. 2018, 10, 124. [CrossRef]
189. Del Rio, D.; Zimetti, F.; Caffarra, P.; Tassotti, M.; Bernini, F.; Brighenti, F.; Zini, A.; Zanotti, I. The Gut Microbial Metabolite
Trimethylamine-N-Oxide Is Present in Human Cerebrospinal Fluid. Nutrients 2017, 9, 1053. [CrossRef]
190. Li, D.; Ke, Y.; Zhan, R.; Liu, C.; Zhao, M.; Zeng, A.; Shi, X.; Ji, L.; Cheng, S.; Pan, B.; et al. Trimethylamine-N-oxide promotes brain
aging and cognitive impairment in mice. Aging Cell 2018, 17, e12768. [CrossRef] [PubMed]
191. Gao, Q.; Wang, Y.; Wang, X.; Fu, S.; Zhang, X.; Wang, R.T. Decreased levels of circulating trimethylamine N-oxide alleviate
cognitive and pathological deterioration in transgenic mice: A potential therapeutic approach for Alzheimer’s disease. Aging
2019, 11, 8642–8663. [CrossRef]
192. Govindarajulu, M.; Pinky, P.D.; Steinke, I.; Bloemer, J.; Ramesh, S.; Kariharan, T.; Rella, R.T.; Bhattacharya, S.; Dhanasekaran,
M.; Suppiramaniam, V.; et al. Gut Metabolite TMAO Induces Synaptic Plasticity Deficits by Promoting Endoplasmic Reticulum
Stress. Front. Mol. Neurosci. 2020, 13, 138. [CrossRef]
193. Brunt, V.E.; LaRocca, T.J.; Bazzoni, A.E.; Sapinsley, Z.J.; Miyamoto-Ditmon, J.; Gioscia-Ryan, R.A.; Neilson, A.P.; Link, C.D.; Seals,
D.R. The gut microbiome-derived metabolite trimethylamine N-oxide modulates neuroinflammation and cognitive function with
aging. Geroscience 2020. [CrossRef] [PubMed]
194. Alkasir, R.; Li, J.; Li, X.; Jin, M.; Zhu, B. Human gut microbiota: The links with dementia development. Protein Cell 2017, 8, 90–102.
[CrossRef]
195. Wang, Z.; Klipfell, E.; Bennett, B.J.; Koeth, R.; Levison, B.S.; Dugar, B.; Feldstein, A.E.; Britt, E.B.; Fu, X.; Chung, Y.M.; et al. Gut
flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472, 57–63. [CrossRef] [PubMed]
196. Gorelick, P.B.; Scuteri, A.; Black, S.E.; Decarli, C.; Greenberg, S.M.; Iadecola, C.; Launer, L.J.; Laurent, S.; Lopez, O.L.; Nyenhuis, D.;
et al. Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the american
heart association/american stroke association. Stroke 2011, 42, 2672–2713. [CrossRef]
197. Wu, P.; Chen, J.; Tao, J.; Wu, S.; Xu, G.; Wang, Z.; Wei, D.; Yin, W. Trimethylamine N-oxide promotes apoE(-/-) mice atherosclerosis
by inducing vascular endothelial cell pyroptosis via the SDHB/ROS pathway. J. Cell Physiol. 2020, 235, 6582–6591. [CrossRef]
[PubMed]
198. Koeth, R.A.; Wang, Z.; Levison, B.S.; Buffa, J.A.; Org, E.; Sheehy, B.T.; Britt, E.B.; Fu, X.; Wu, Y.; Li, L.; et al. Intestinal microbiota
metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 2013, 19, 576–585. [CrossRef] [PubMed]
199. Zhu, W.; Gregory, J.C.; Org, E.; Buffa, J.A.; Gupta, N.; Wang, Z.; Li, L.; Fu, X.; Wu, Y.; Mehrabian, M.; et al. Gut Microbial
Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell 2016, 165, 111–124. [CrossRef] [PubMed]
200. Janeiro, M.H.; Ramírez, M.J.; Milagro, F.I.; Martínez, J.A.; Solas, M. Implication of Trimethylamine N-Oxide (TMAO) in Disease:
Potential Biomarker or New Therapeutic Target. Nutrients 2018, 10, 1398. [CrossRef] [PubMed]
201. Xu, R.; Wang, Q. Towards understanding brain-gut-microbiome connections in Alzheimer’s disease. BMC Syst. Biol. 2016, 10
(Suppl. S3), 63. [CrossRef]
202. Hulme, H.; Meikle, L.M.; Strittmatter, N.; van der Hooft, J.J.J.; Swales, J.; Bragg, R.A.; Villar, V.H.; Ormsby, M.J.; Barnes, S.; Brown,
S.L.; et al. Microbiome-derived carnitine mimics as previously unknown mediators of gut-brain axis communication. Sci. Adv.
2020, 6, eaax6328. [CrossRef] [PubMed]
Nutrients 2021, 13, 732 40 of 40
203. Knobloch, M.; Pilz, G.A.; Ghesquière, B.; Kovacs, W.J.; Wegleiter, T.; Moore, D.L.; Hruzova, M.; Zamboni, N.; Carmeliet, P.;
Jessberger, S. A Fatty Acid Oxidation-Dependent Metabolic Shift Regulates Adult Neural Stem Cell Activity. Cell Rep. 2017,
20, 2144–2155. [CrossRef] [PubMed]
204. Xie, Z.; Jones, A.; Deeney, J.T.; Hur, S.K.; Bankaitis, V.A. Inborn Errors of Long-Chain Fatty Acid β-Oxidation Link Neural Stem
Cell Self-Renewal to Autism. Cell Rep. 2016, 14, 991–999. [CrossRef]
205. Argou-Cardozo, I.; Zeidán-Chuliá, F. Clostridium Bacteria and Autism Spectrum Conditions: A Systematic Review and Hypo-
thetical Contribution of Environmental Glyphosate Levels. Med. Sci. 2018, 6, 29. [CrossRef]
206. Ho, L.; Zhao, D.; Ono, K.; Ruan, K.; Mogno, I.; Tsuji, M.; Carry, E.; Brathwaite, J.; Sims, S.; Frolinger, T.; et al. Heterogeneity in gut
microbiota drive polyphenol metabolism that influences α-synuclein misfolding and toxicity. J. Nutr. Biochem. 2019, 64, 170–181.
[CrossRef] [PubMed]
207. Wang, D.; Ho, L.; Faith, J.; Ono, K.; Janle, E.M.; Lachcik, P.J.; Cooper, B.R.; Jannasch, A.H.; D’Arcy, B.R.; Williams, B.A.; et al.
Role of intestinal microbiota in the generation of polyphenol-derived phenolic acid mediated attenuation of Alzheimer’s disease
β-amyloid oligomerization. Mol. Nutr. Food Res. 2015, 59, 1025–1040. [CrossRef]
208. Reddy, V.P.; Aryal, P.; Robinson, S.; Rafiu, R.; Obrenovich, M.; Perry, G. Polyphenols in Alzheimer’s Disease and in the Gut-Brain
Axis. Microorganisms 2020, 8, 199. [CrossRef] [PubMed]
209. Filosa, S.; Di Meo, F.; Crispi, S. Polyphenols-gut microbiota interplay and brain neuromodulation. Neural Regen. Res. 2018,
13, 2055–2059. [CrossRef] [PubMed]
210. Feng, X.; Li, Y.; Brobbey Oppong, M.; Qiu, F. Insights into the intestinal bacterial metabolism of flavonoids and the bioactivities of
their microbe-derived ring cleavage metabolites. Drug Metab. Rev. 2018, 50, 343–356. [CrossRef]
211. Gasperotti, M.; Passamonti, S.; Tramer, F.; Masuero, D.; Guella, G.; Mattivi, F.; Vrhovsek, U. Fate of microbial metabolites of
dietary polyphenols in rats: Is the brain their target destination? ACS Chem. Neurosci. 2015, 6, 1341–1352. [CrossRef]
212. Cheng, C.Y.; Su, S.Y.; Tang, N.Y.; Ho, T.Y.; Chiang, S.Y.; Hsieh, C.L. Ferulic acid provides neuroprotection against oxidative
stress-related apoptosis after cerebral ischemia/reperfusion injury by inhibiting ICAM-1 mRNA expression in rats. Brain Res.
2008, 1209, 136–150. [CrossRef] [PubMed]
213. Yabe, T.; Hirahara, H.; Harada, N.; Ito, N.; Nagai, T.; Sanagi, T.; Yamada, H. Ferulic acid induces neural progenitor cell proliferation
in vitro and in vivo. Neuroscience 2010, 165, 515–524. [CrossRef]
214. Fuertes, A.; Perez-Burillo, S.; Apaolaza, I.; Valles, Y.; Francino, M.P.; Rufian-Henares, J.A.; Planes, F.J. Adaptation of the Human
Gut Microbiota Metabolic Network During the First Year After Birth. Front. Microbiol. 2019, 10, 848. [CrossRef] [PubMed]
215. Fullana, M.A.; Albajes-Eizagirre, A.; Soriano-Mas, C.; Vervliet, B.; Cardoner, N.; Benet, O.; Radua, J.; Harrison, B.J. Fear extinction
in the human brain: A meta-analysis of fMRI studies in healthy participants. Neurosci. Biobehav. Rev. 2018, 88, 16–25. [CrossRef]
[PubMed]
216. Singewald, N.; Holmes, A. Rodent models of impaired fear extinction. Psychopharmacology 2019, 236, 21–32. [CrossRef] [PubMed]
217. Friedland, R.P.; Chapman, M.R. The role of microbial amyloid in neurodegeneration. PLoS Pathog. 2017, 13, e1006654. [CrossRef]
218. Lundmark, K.; Westermark, G.T.; Olsén, A.; Westermark, P. Protein fibrils in nature can enhance amyloid protein A amyloidosis
in mice: Cross-seeding as a disease mechanism. Proc. Natl. Acad. Sci. USA 2005, 102, 6098–6102. [CrossRef]
219. Svensson, E.; Horváth-Puhó, E.; Thomsen, R.W.; Djurhuus, J.C.; Pedersen, L.; Borghammer, P.; Sørensen, H.T. Vagotomy and
subsequent risk of Parkinson’s disease. Ann. Neurol. 2015, 78, 522–529. [CrossRef]
220. Pan-Montojo, F.; Schwarz, M.; Winkler, C.; Arnhold, M.; O’Sullivan, G.A.; Pal, A.; Said, J.; Marsico, G.; Verbavatz, J.M.; Rodrigo-
Angulo, M.; et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in
mice. Sci. Rep. 2012, 2, 898. [CrossRef]
221. Miraglia, F.; Colla, E. Microbiome, Parkinson’s Disease and Molecular Mimicry. Cells 2019, 8, 222. [CrossRef] [PubMed]
222. Bienenstock, J.; Kunze, W.A.; Forsythe, P. Disruptive physiology: Olfaction and the microbiome-gut-brain axis. Biol. Rev. Camb.
Philos. Soc. 2018, 93, 390–403. [CrossRef] [PubMed]
223. Sampson, T.R.; Challis, C.; Jain, N.; Moiseyenko, A.; Ladinsky, M.S.; Shastri, G.G.; Thron, T.; Needham, B.D.; Horvath, I.; Debelius,
J.W.; et al. A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice. Elife 2020, 9. [CrossRef]
[PubMed]
224. Chen, S.G.; Stribinskis, V.; Rane, M.J.; Demuth, D.R.; Gozal, E.; Roberts, A.M.; Jagadapillai, R.; Liu, R.; Choe, K.; Shivakumar, B.;
et al. Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344
Rats and Caenorhabditis elegans. Sci. Rep. 2016, 6, 34477. [CrossRef]
225. Caputi, V.; Giron, M.C. Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson’s Disease. Int. J. Mol. Sci. 2018, 19, 1689.
[CrossRef] [PubMed]
226. Yang, D.; Zhao, D.; Shah, S.Z.A.; Wu, W.; Lai, M.; Zhang, X.; Li, J.; Guan, Z.; Zhao, H.; Li, W.; et al. Implications of gut microbiota
dysbiosis and metabolic changes in prion disease. Neurobiol. Dis. 2020, 135, 104704. [CrossRef]
227. Blacher, E.; Bashiardes, S.; Shapiro, H.; Rothschild, D.; Mor, U.; Dori-Bachash, M.; Kleimeyer, C.; Moresi, C.; Harnik, Y.; Zur, M.;
et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature 2019, 572, 474–480. [CrossRef]
